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FOREWORD
As the use of marijuana has increased over the last several
years, the need for improved quantitative chemical assays with
which to study the impact of marijuana use on the health of the
individual has grown. More sensitive, reliable, and workable assays
for cannabinoids (the active principles of marijuana) in body fluids
are essential to increase our knowledge of how these chemical con-
stituents and their metabolites accumulate and how they are elimi-
nated from the body.
In addition to research requirements, there is a growing demand
for less expensive and more reliable tests for use by the armed
forces, civilian law enforcement agencies, and private industry
where concern exists for the impact of marijuana use on critical job
performance. Of particular concern are the effects of marijuana on
complex performance related to driving motor vehicles, piloting
aircraft, operating industrial equipment, monitoring radar screens,
etc.
Concern about the negative impact of marijuana use on health
has been elevated by recent research findings as well as the avail-
ability of more potent marijuana, the trend toward use among
younger age groups, and the growing numbers of individuals with
long-term exposure to marijuana. On the positive side of the health
issue, tetrahydrocannabinol (THC), the primary active component
of marijuana, is under intense investigation as a treatment for the
often intolerable side effects of chemotherapy when other antieme-
tics are ineffective. Potential uses of THC for treatment of the
symptoms of glaucoma, spasms related to muscular dystrophy, and
certain asthmatic conditions are also under investigation. Research
to assess both the clinical potential of THC and the effects of mari-
juana on health must rely in part on sensitive chemical analyses.
Differing methodologies for cannabinoid analysis are required to
accommodate these various needs. Accordingly, the National Insti-
tute on Drug Abuse (NIDA) has supported a variety of efforts to
develop sensitive cannabinoid assay methods by techniques of im-
munoassay, gas chromatography, gas chromatography/mass spec-
trometry, and high-performance liquid chromatography. The devel-
opment of these methods was the subject of a technical review held
by NIDA in February 1976 and described in NIDA Research Mono-
graph 7. Since that time, research on techniques in the analysis of
cannabinoids in biological fluids has been refined and new methods
have been developed. Even more important, perhaps, has been the
application of many of these methods to a wide variety of research
problems.
In January 1980 NIDA held a second technical review to bring
together key scientists working on the development of cannabinoid
assays and to summarize recent research where cannabinoid analy-
sis is being used. The present monograph presents this information
as a compendium of the state of the art in the rapidly developing
field of cannabinoid analysis research today.
It is our hope that this volume will be useful to basic researchers
in the fields of biomedical and forensic science, where the availabil-
ity of reliable, accurate, and accessible quantitative assays is criti-
cal to a better understanding of issues in marijuana abuse.
Marvin Snyder, Ph.D.
Director
Division of Research
National Institute on Drug Abuse
vi
CONTENTS
Foreword
Marvin Snyder 
Introduction and Overview
Richard L. Hawks
The Use of High-Pressure Liquid Chromatography with
Electrochemical Detection for the Assay of Nantradol and its
Application to -Tetrahydrocannabinol
Richard M. Shepard and George M. Milne
Radioimmunoassays for Cannabinoids
C. E. Cook, H. H. Seltzman, V. H. Schindler, C. R. Tallent,
K. M. Chin, and C. G. Pitt
Radioimmunoanalysis of Delta-9-THC in Blood by Means of an
125I Tracer
S. M. Owens, A. J. McBay, and H. M. Reisner
Significant Developments in Radioimmune Methods Applied
to -THC and its 9-Substituted Metabolites
J. R. Soares, J. D. Grant, and S. J. Gross
Combined High-Performance Liquid Chromatography and
Radioimmunoassay Method for the Analysis of
Tetrahydrocannabinol and its Metabolites in Plasma and
Urine
v
Anthony C. Moffat, Peter L. Williams, and Laurence J.
King
An EMIT Assay for Cannabinoid Metabolites in Urine
M. J. deLaurentis, K. McNeil, A. J. Mann, S. Clark, and
Helena M. Greenwood
Laboratory Evaluation of Immunoassay Kits for the Detection
of Cannabinoids in Biological Fluids
Michael A. Peat, Bryan S. Finkle, and Mary E. Deyman
1
7
19
33
44
56
69
85
vii
Quantitative Analysis for -THC, 11-Hydroxy- -THC, and 9-
Carboxy- -THC in Plasma Using GC/CI-MS
Rodger L. Foltz and Bruce J. Hidy 99
Stability of -Tetrahydrocannabinol in Stored Blood and
Serum
Anthony S. Wong, Michael W. Orbanosky, Victor C. Reeve,
and James D, Beede 119
The Constituents of Cannabis and the Disposition and
Metabolism of Cannabinoids
Richard L. Hawks 125
List of Monographs 138
viii
Analysis of Cannabinoids
Research Monograph 42, R. Hawks, Editor
National Institute on Drug Abuse, 1992
Introduction and Overview
Richard L. Hawks
The analysis of cannabinoids in biological fluids is a subject of
considerable interest in several areas of public concern and also a
subject of tremendous scientific challenge. Scientists involved in
basic research on marijuana and its components are demanding
more sensitive and accessible methode of quantitative analysis,
civil enforcement organizations are interested in more effective
ways of chemically determining intoxication or past use of marijua-
na, and professionals in the clinical field are becoming increasingly
interested in tests to determine the extent of an individual’s mari-
juana use habit in conjunction with treatment protocols.
In any area of assay development, and particularly in the drug
abuse area, the questione of method sensitivity, specificity, and reli-
ability are paramount. Another related but often overlooked area
is that of drug pharmacokinetics, critical to the interpretation of a
drug-concentration analysis,
The sensitivity of an assay is a measure of the least amount of
material the assay will reliably detect. Because there are many
ways to arrive at a number which represents this limit, the sensi-
tivity claims for published assays do not always coincide with their
practical working limits. When eeneitivity is determined it is im-
portant to consider the type of body fluid involved and the way the
sensitivity is determined. An assay which reliably detects one nan-
ogram of a given drug in one milliliter of saline may not provide
reliable detection at even 100 times that concentration in an actual
serum or urine sample because of the interference of biological
background noise. When determining the sensitivity of an assay it
is important to prepare and analyze a significant number of blank
body-fluid samples containing the same amount of analyte near the
limit of sensitivity so that the precision of the assay can be statisti-
cally determined. The statistical variation of this “spiked” level
1
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should be compared with the variation observed in the blank sam-
ples to determine the probability of overlapping values. This is par-
ticularly important in assays designed for use as detection assays
where there is concern for both false positive results and false neg-
ative results.
It is equally important to be able to distinguish the given drug of
interest from other drugs, metabolites, and endogenous compounds
that might appear in the sample matrix. The extent to which the
assay can make this distinction is the specificity of the assay. This
becomes particularly important in the case of forensic samples,
where the qualitative analysis of the drug is often more important
than the quantitative analysis. In the case of immunoassays, speci-
ficity is a particularly important factor. Historically, immunoas-
says have lacked high specificity because of the way antibody mate-
rial was generated. As demonstrated in the papers presented by
Drs. Cook and Soares, high specificity of radioimmunoassay (RIA)
methods can be achieved by careful design and sophisticated tech-
niques of synthesis in the preparation of the immunogens used to
generate the reagent antisera. In some cases, however, an assay
with high specificity for a specific parent drug or metabolite is not
as desirable as one with limited cross-reactivity for a class of mole-
cules, as in the case of the Syva homogeneous enzyme immunoas-
say (EMIT) presented by Drs. Greenwood and deLaurentis. Here
cross-reactivity with a variety of -tetrahydrocannabinol (THC)
metabolites is desirable since the assay is used to determine past
use of marijuana rather than a specific level of a given cannabin-
oid. By cross-reaction with more than a single metabolite, addition-
al sensitivity is achieved.
Another analytical approach which benefits from the use of
cross-reacting antisera is that which combines high-performance
liquid chromatography (HPLC) with an RIA. This technique ex-
ploits the specificity to be achieved by HPLC chromatographic sep-
aration and the sensitivity possible by using an RIA as the detector
for the system. A good example of this approach is described in the
paper by Dr. Moffat.
Major advances since the time of the previous NIDA monograph
on cannabinoid assays in 1976 have included the development of
sensitive gas chromatography/mass spectrometry (GC/MS) meth-
ods for the detection of 11-hydroxy-THC and 11-nor-THC-9-carboxy-
lic acid (9-carboxy-THC) at low-nanogram sensitivity. New achieve-
ments in immunoassays include the development of specific RIA
methods for 9-carboxy-THC as well as the development of iodinated
tracers which allow sensitivity levels near one nanogram per ml to
be achieved. The demonstrated ability to use some of these assays
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for direct analysis of whole blood is also an important achievement
for forensic research applications.
Detection of past use of marijuana could facilitate drug-treat-
ment counseling and provide a broader base by which to assess the
impact of marijuana on health and safety. This is of particular con-
cern with respect to those groups which might be considered to be
in relatively high-risk situations, either to themselves or others,
and includes the young, members of the military, automobile driv-
ers, and operators of complex industrial equipment. Systems like
the Syva EMIT may provide some of this assessment in its role as a
screening tool for particular populations.
In the case of drivers, equipment operators, and others whose
level of sobriety is a key safety factor, the issue of an analytical
means of determining intoxication is critical and a matter that has
proven to be a much more difficult problem than mere detection.
There are many specific factors to be considered when cannabinoid
assays are used in the forensic area, including the convenience of
obtaining the biological sample to be analyzed and the usual con-
cerns of sensitivity, specificity, and other technical aspects of the
assay. Interpretation of results  in forensic cases becomes as impor-
tant as the accuracy of the assay performed.
It appears from available data that only a blood sample may cor-
relate physiologically with an actual state of intoxication. A urine
sample which tests positive indicates prior use, but such an analy-
sis cannot be directly related to intoxication since cannabinoid me-
tabolites can persist in the urine for several days after smoking a
single cigarette.
The use of saliva or breath for detection is very attractive be-
cause it involves an easily obtainable sample. Studies are in prog-
ress to further assess the potential of saliva or breath as a noninva-
sive alternative to blood collection in roadside surveys. Dr Soares’
paper provides preliminary evidence that cannabinoids detectable
by immunoassay techniques may be found in breath samples.
While experiments involving intravenous injection of radiolabeled
THC into human subjects with subsequent monitoring of radioac-
tivity in saliva have indicated that negligible amounts of drug or
metabolites cross the blood/saliva barrier, other experiments have
shown that breath and blood samples collected after smoking mari-
juana do show detectable levels of THC which persist for several
hours. These THC levels are apparently due to material seques-
tered directly, in a nonspecific way, in the mouth and lungs during
smoking and then slowly released into breath or saliva. If simple
methods for the analysis of these levels could be developed, it is
conceivable that they could be used as a presumptive test of recent
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use of marijuana. Such a method of analysis would not, however,
be quantitatively related to blood-level equivalents under these cir-
cumstances.
One of the most important issues in the area of marijuana and
driving is the interpretation of a given blood concentration of THC
to explain the presumptive intoxication of the individual from
whom the sample was taken. In an attempt to determine whether
it is feasible to establish a presumptive level of impairment for
THC, studies were initiated under NIDA contract at the Southern
California Research Institute to study the effects of various doses of
marijuana on behavioral tasks related to driving ability. Coincident
with the behavioral study, a pharmacokinetic analysis of each sub
ject was performed. These studies were designed to generate two
sets of time-course data-one of blood concentrations and one of be-
havioral performance. The sensitive behavioral tests were carried
out periodically to provide a performance time-course curve which
could be statistically compared to the pharmacokinetic blood-level
curve. Analysis of this data is not yet complete, but what is obvious
so far is that even though some consistency exists across individ-
uals smoking a given dose of marijuana, in terms of expected blood
levels, the associated performance effects of these doses do not
show the same consistency. It is not yet clear whether a practical
presumptive concentration of THC can be related to measurable
impairment.
Research on the therapeutic use of THC is a rapidly developing
area. Large State and national programs have been started to in-
vestigate the therapeutic potential of THC as an antiemetic for
chemotherapy patients. Most of this research involves oral formu-
lations of THC in sesame oil capsules. The chapter on metabolism
and disposition indicates that the oral route of administration pro-
duces a relatively large amount of 11-hydroxy-THC, which is a
pharmacologically active metabolite, and an assay suitable for this
type of clinical research must be designed to determine both THC
and 11-hydroxy-THC levels. At the present time only the CC/MS
method and methods which couple HPLC with RIA can be applied
to this type of analysis. It is expected however that a specific RIA
method being tested at the Research Triangle Institute will be
available soon for separately determining 11-hydroxy THC in the
presence of THC.
There has been increasing interest in the use of nonspecific
RIA’s in combination with the chromatographic separation proper-
ties of HPLC instruments. The paper by Dr. Moffat demonstrates
one particular use of this system in the area of cannabinoid analy-
ses. The combination of these two methods constitutes a powerful
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research tool in that it enables the investigator to determine quan-
titatively with a single radioimmunoassay the concentrations of a
large number of metabolites. The tradeoff is a somewhat longer
time of analysis, but in a research setting or with a small number
of samples, time is not often a major factor. HPLC has also been
used as an integral part of the sample preparation procedure for
GC/MS analyses, as noted by Dr. Foltz. Drs. Shepard and Milne
report a method of reasonable sensitivity with use of HPLC and
standard detectors.
Dr. Moffat, in forensic cases examined by his group, reports sig-
nificant amounts of glucuronide-conjugated metabolites in urine
and blood. Dr. Peat reported that a large number of EMIT-positive
urine samples, when subsequently analyzed by GC/MS, showed
levels that were low or undetectable for free 9-carboxy-THC. In
view of Dr. Moffat’s comments, further analysis of some of these
samples (after the technical review) was carried out. In a number
of cases, samples previously low or negative for 9-carboxy-THC
showed significant levels after enzymatic hydrolysis. This finding
indicates that in some urine samples virtually all of the 9-carboxy-
THC may be found in a conjugated form, an important factor when
a specific method such as GC/MS is used as a confirmation tool for
a less specific assay such as the EMIT, which probably cross-reacts
with the glucuronide metabolite. This hydrolysis technique has
been applied to the confirmation of a large number of EMIT-posi-
tive samples resulting from a Department of Defense screening
study. The Armed Forces Institute of Pathology used GC/MS to
confirm over 95 percent of 1100 positive urine samples resulting
from the study. Most of the questionable positive results which
made up the 5 percent unconfirmed cases were close to the cutoff
level of detection of the EMIT assay.
Dr. Owens reported that his highly specific and sensitive RIA
worked quite well with a methanol extract of whole blood. Previ-
ously, many investigators assumed that, for an immunoassay to
function properly, the medium in which the antigen-antibody inter-
action occurred would have to be quite similar to a normal physio-
logical environment. It appears, however, that at least in the case
of the cannabinoid RIAs, this is not necessarily the case. In fact the
assay was shown to work better in the presence of alcohol than in
its absence. This also had been the experience of Drs. Moffat and
Cook, an important finding because it enables a blood sample to be
partially purified by alcohol precipitation, centrifugation, and sub-
sequent analysis of the resulting alcoholic supernatant without an
evaporation step. The presence of alcohol may facilitate the assay
by reducing “sticking” of THC to nonspecific binding sites.
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Of interest to the forensic community are the comments of Dr.
Wong concerning his studies on the stability of cannabinoids in
whole blood and plasma under different conditions. These studies
were carried out under contract to the Department of Justice,
State of California, as part of that State’s research efforts to pro-
vide a basis for future legislation concerning marijuana and driv-
ing impairment.
Interpretation of data from forensic samples was an issue of con-
siderable discussion at this technical review. Because THC has a
relatively short half-life after smoking, assay method sensitivity of
1 ng per ml may not be sufficient to detect the compound more
than 6 hours after smoking. This has led some investigators to
argue that if any level of THC is detectable in blood at all, one can
assume that the sample was taken at a time very close to the inci-
dent of smoking and that, therefore, the subject has a high prob-
ability of being intoxicated. This argument makes fairly broad as-
sumptions concerning the presumptive concentrations of THC that
can be related to specific types of intoxicated behavior. Quite obvi-
ously we are still a long way from determining exactly what this
presumptive level is. It was generally agreed, however, that for any
THC blood assay to be of use in the forensic area, it would have to
have a sensitivity of at least 3 nanograms per ml since blood levels
fall to this level within an hour or two after a smoking incident.
While little information is currently available on THC blood levels
in chronic smokers, the possibility of accumulated drug being at de-
tectable levels long after the acute period of intoxication must be
considered.
While it is obvious that considerable progress has been made in
the last few years on cannabinoid assays, research in this area con-
tinues to develop at a rapid pace. From the presentations and dis-
cussions at this meeting, it seems that the immediate future holds
interesting breakthroughs in even more sensitive assays as well as
improvements in methods which will lead to cannabinoid assays
being used for the first time in a variety of new forensic and social
settings.
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The Use of High-Pressure Liquid
Chromatography with
Electrochemical Detection for the
Assay of Nantradol and its
Application to
Tetrahydrocannabinol
Richard M. Shepard and George M. Milne
High-pressure liquid chromatography with electrochemical
detection permits sensitive, selective and quantitative anal-
ysis of biological and pharmaceutical compounds contain-
ing electroactive functional groups. In support of pharmacol-
logical and clinical studies with nantradol, a potent, non-
opioid analgetic, a specific HPLC/electrochemical assay for
nantradol and related compounds in plasma was recently
developed. In preliminary studies we have now extended
this technique to the detection of and 11-OH
tetrahydrocannabinol. Results are resented which indicate
that HPLC coupled to an electroc emical detector providesh
sensitivity for these compounds in plasma in the low ng/ml
range.
INTRODUCTION
High-performance liquid chromatography (HPLC) is finding in-
creasing application to the trace analysis of drugs, drug metabo-
lites and biologically important compounds in complicated matrices
such as body fluids and tissue samples. In the case of cannabinoids,
HPLC has been used as a means of purifying
tetrahydrocannabinol ( -THC) from related materials and interfer-
ing endogenous materials in blood plasma. However, at the concen-
7
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trations of -THC normally encountered in plasma, the direct
HPLC on-line monitoring methods such as refractive index or ul-
traviolet spectrophotometry detection are not sensitive enough for
use in plasma level monitoring. As a result, subsequent analysis by
gas chromatography (1), mass spectrometry (2), or radioimmunoas-
say (3) has been required. The coupling of electrochemical detection
to HPLC (4) is a recently developed technique that often provides
the sensitivity and selectivity necessary for practical analytical pro
cedures. The application of this technology to the determination in
plasma of nantradol, a potent analgetic, has recently been de
scribed (5). It is the aim of this paper to describe briefly the princi-
ples of electrochemical detection linked to HPLC, to examine the
application of this technique to the analysis of nantradol in
plasma, and then to discuss efforts to extend this method to the de-
termination of -THC in plasma.
PRINCIPLES OF HPLC COUPLED WITH
ELECTROCHEMICAL DETECTION
In HPLC with electrochemical detection (figure 1), material
eluted from the chromatographic column reacts at an electrode
surface under controlled potential conditions, and the current
which results from the net exchange of electrons is monitored as a
function of time (6). Since the amount of material converted by the
electrochemical reaction is proportional to the instantaneous con-
centration, the current will be directly related to the amount of
compound eluted as a function of time. If chromatographic condi-
tions are carefully controlled, then amperometric detection is quite
precise, with a wide linear range of typically 104, and quantitative
data can be obtained at the picomole level for many compounds.
Limits of detection down to 1 pg or less are attainable in some
cases.
In addition to being extremely sensitive, the electrochemical de-
tector is selective in that only compounds containing an electro-
chemically oxidizable or reducible functional group can be detected
(6). Furthermore, these compounds must be electroactive at the
given potential to which the detector is set. While these features
represent both an advantage and disadvantage, they often combine
to make sample preparation a relatively simple matter.
With direct conversion of a chemical signal into an electrical
signal, the electronic instrumentation of the electrochemical detec-
tor is therefore inexpensive and reliable. The detector cell is well
suited for HPLC analysis because it has an extremely low dead
volume. Because of the nature of electrochemical detection, the
HPLC ASSAY FOR NANTRADOL
Picomole sensitivity
Selective
Low cost
Can be combined with HPLC
Used in analysis of:
phenols
aromatic amines
catecholamines
antioxidants
ascorbic acid
uric acid
natural products
pharmaceuticals
FIGURE 1. Features and applications of electrochemical detection.
chromatographic systems most promising for this type of detector
are ion-exchange and reversed-phase systems where aqueous or
aqueous-alcohol solvent mixtures containing some dissolved ions
can be used (6).
A number of endogenous compounds, drugs, and drug metabo-
lites have been studied by HPLC with electrochemical detection.
Examples include phenols (7), aromatic amines (6,8), catechola-
mines (9,10,11), ascorbic acid (12) and uric acid (13). This methodolo-
gy has found increasing application in the field of neurochemical
analysis, having been used for the simultaneous determination, in
rat and mouse brains, of nanogram levels of catecholaminergic and
serotonergic neurotransmitters such as norephinephrine, dopa-
mine, tryptophan and serotonin (14,15).
APPLICATION OF HPLC AND ELECTROCHEMICAL
DETECTION TO NANTRADOL
Nantradol (figure 2) produces analgetic activity 2 to 7 times
greater than morphine across a range of analgetic tests traditional-
ly responsive only to the narcotic agonist analgetics, but it does not
bind to the opiate receptor in vitro (16). While nantradol possesses
certain features of cannabinoid pharmacology, it has a number of
structural features which distinguish it from the cannabinoids-in-
cluding the absence of a pyran oxygen, the presence of a weakly
basic nitrogen and the introduction of an oxygen-containing aide
chain. In vivo nantradol is rapidly deacetylated to the free phenol,
desacetylnantradol, which is the only form of the drug detectable
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in plasma (figure 2). The phenol function, which is shared with
THC, makes possible the electrochemical detection of desacetylnan-
tradol.
FIGURE 2. Structure of nantradol (CP-44,001), a potent non-opioid analgetic, and its
deacetylation to desacetylnantradol (CP-44,041).
Fortification of 2 ml plasma sample with internal standard
(N-methyl analog)
Extraction with 2% isopropanol in diethyl ether
Purification of drug by adsorption to and elution from
Sephadex C-25 (cation exchanger)
Analysis by reversed-phase HPLC with electrochemical detection
FIGURE 3. Flow scheme outlining the procedure for the analysis of
desacetylnantradol in plasma.
The assay procedure (figure 3) begins with the fortification of a 2
ml plasma sample with 20 ng/ml of an internal standard, the N-
methyl analog of desacetylnantradol (5,17). Extraction of the drug
and internal standard is achieved with 2% isopropanol in diethyl
ether. The extract is added to 2 ml of methanol and concentrated
under nitrogen to a final volume of 1 ml. The extracted drug and
internal standard are then adsorbed onto cation exchanger Sepha-
dex C-25 (added in 1 ml as a 30% suspension in water), collected by
centrifugation and the supernatant discarded. Following a water
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wash, the desacetylnantradol and internal standard are eluted
from the Sephadex C-25 with 1 ml of acetonitrile:0.05 M KH2PO4
(1:1). Analysis is achieved by injection of 50 µl of the assay solution
onto a reversed-phase HPLC Waters µBondapak phenyl column
eluted with a solvent system of acetonitrile:0.05 M KH2PO4 (1:1) at a
flow rate of 2.0 ml/min. Two typical HPLC chromatograms of the
analysis of desacetylnantradol isolated from human plasma sam-
ples fortified with 20 ng/ml of internal standard and either 5 or 20
ng/ml of drug are shown in figure 4. Unknown drug levels are first
expressed as the ratio of the peak height corresponding to desace-
tylnantradol versus that for 20 mg/ml of the internal standard.
Concentrations are then determined from an appropriately con-
structed standard curve (figure 5), in which known amounts of drug
have been added to plasma. Good linearity is obtained and the pre-
cision of the assay is about 10% relative standard deviation based
on the mean normalized peak height ratios within an assay series.
The sensitivity of the assay permits the analysis of desacetylnan-
tradol in plasma down to levels of about 5 ng/ml. As little as 200
pg of drug injected on-column can be detected.
APPLICATION OF HPLC/ELECTROCHEMICAL DETECTION
TO -THC
In light of the common presence of a C-1 phenol in desacetylnan-
tradol and -THC, we have carried out some initial experiments
designed to investigate the feasibility of analyzing - THC using
HPLC with electrochemical detection. The HPLC system for the
analysis of nantradol was adapted to -THC by using the same re-
versed-phase column and detector potential and is probably not op-
timal. A less polar solvent of 55:45 acetonitrile:0.05 M KH2PO4 at a
flow rate of 2.0 ml/min was used. In this system -THC and 11-
hydroxy -tetrahydrocannabinol (11-OH - THC), are readily sepa-
rated from each other (figure 6), eluting at 16.6 ml and 8.2 ml, re-
spectively. As little as 0.7 ng of pure -THC injected on-column
can be detected in this system. When various amounts of pure
THC, from 0.7 ng to 154 ng, are injected onto the column the re-
sulting peak response curve is linear over the entire range with a
correlation coefficient of 0.999 and a precision of 6.3% relative
standard deviation based on the mean normalized peak heights
(figure 7).
In preliminary attempts to determine -THC levels in plasma,
dog plasma (2 ml) was extracted three times with hexane (3 ml).
The pooled hexane extracts were washed 3 times with 3% KOH in
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FIGURE 4. HPLC chromatograms of desacetylnantradol and internal standard
isolated from human plasma, fortified with 20 ng/ml of N-methyl-
desacetylnantradol and either a) 5 ng/ml or b) 20 ng/ml of desacetylnantradol.
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FIGURE 5. Standard curve illustrating the changes in the ratio of the peak heights
of desacetylnantradol versus internal standard as a function of varying
concentrations of desacetylnantradol in fortified human plasma.
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FIGURE 6. HPLC chromatogram illustrating the detection and separation of
THC and 11-OH- -THC.
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FIGURE 7. Demonstration of the linearity of peak height response of -THC versus
the amount injected onto the HPLC, using electrochemical detection.
20% aqueous methanol. The pooled alkali extracts were acidified
with concentrated HCl, diluted with water and back-extracted with
hexane. This hexane extract was then evaporated under nitrogen
and the residue was redissolved in 200 µ1 of HPLC solvent. 100 µ1
of the solution was then injected onto the column. The HPLC pro-
files obtained from blank dog plasma and dog plasma fortified with
20 ng/ml -THC are shown in figure 8. The average recovery of
-THC in three samples was 38% ± 2%. Based on these results,
the limit of detection for the plasma determination of -THC by
this procedure is approximately 5 ng/ml.
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FIGURE 8. HPLC chromatograms of -THC isolated from a) blank dog plasma and
b) dog plasma fortified with 20 ng/ml -THC.
CONCLUSION
HPLC with electrochemical detection can often provide the sensi-
tivity and selectivity necessary for practical analytical procedures,
as in the case of nantradol. It has been demonstrated here that thie
methodology is capable of detecting low nanogram levels of -THC
in plasma while providing a separation of -THC from its major
metabolite 11-OH- -THC. Thus it appears that, while further de-
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velopment of this technique is needed for a routine plasma assay
for -THC and its metabolites, HPLC with electrochemical detec-
tion is a feasible approach to the analysis of nanogram concentra-
tions of -THC.
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Radioimmunoassays for
Cannabinoids
C. E. Cook, H. H. Seltzman, V. H. Schindler, C. R.
Tallent, K. M. Chin, and C. G. Pitt
The simplicity, sensitivity, and specificity of radioimmun-
oassay have made it an attractive procedure for the analy-
sis of delta-9-tetrahydrocannabinol (THC) in biological
fluids or tissues. The presence of closely related compounds
such as metabolites may interfere with radioimmunoassay
results. Appriopriate design of immunogens may diminish
such interference. This work has been directed towards the
use of the amyl side chain for linking cannabinoid com-
pounds to proteins to form immunogens. Although the amyl
side chain is metabolized to some extent, the metabolites
are not quantitatively significant in most cases. 5’-Carboxy-
delta-8-THC and 5’-carboxy-delta-9-THC were linked to
bovine serum albumin. Immunization of rabbits with the
resulting conjugates resulted in the formation of antisera
with high selectivity for delta-9-THC vs. its carboxylic acid
metabolite, 11-nor-9-carboxy-delta-9-THC. Delta-8-THC ra-
dioligands (4’,5’-tritium and 5’-iodine-125) could be used
with these antisera for analysis of delta-9-THC in plasma.
Sensitivity with tritium-labeled material is about 2.5 ng/
ml. 5’-Oxo-11-nor-9-carboxy-delta-8-THC was used to prepare
an immunogen which led to the genemtion of an antiserum
highly specific for 11-nor-9-carboxy-delta-9-THC. This anti-
serum and iodine-125-5’-iodo-11-nor-9-carboxy-delta-8-THC
were used to develop a highly specific assay for 11-nor-9-
carboxy-delta-9-THC in plasma.
INTRODUCTION
The basic premise of immunoassay techniques is that a labeled
antigen will interact with a specific antibody to form a labeled
antigen/antibody complex. In the presence of unlabeled antigen
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there will be a competition for binding sites to the antibody, there-
by decreasing the amount of the complex which is labeled. In order
to achieve a useful assay, then, one must be able to obtain a la-
beled antigen, to generate a specific antibody which will bind the
compound of interest, and to develop some means of distinguishing
the labeled complex from the free labeled antigen.
In order to stimulate the formation of antibodies which will se-
lectively bind a small molecule such as tetrahydrocannabinol, the
molecule or hapten must first be linked to a large molecule, gener-
ally a protein (figure 1). This concept was demonstrated by Land-
steiner many years ago (1). Landsteiner also showed that the posi-
tion of the linkage was of considerable importance in determining
the selectivity of the resulting antibody. The fit between antibody
and antigen is often quite good, particularly in areas which are re-
moved from the site of attachment to the protein. However, intro-
duction of the covalent link inevitably results in a change in the
structural characteristics of the molecule. The resulting antibody
often reflects this by being insensitive to changes around the posi-
tion of linkage, as is illustrated by the hatched area in figure 1.
FIGURE 1. Generation of antibodies to a drug. The drug (hapten component) is
covalently linked to a large molecule such as a protein to form the immunogen.
Injection of this into animals stimulates formation of antibodies. The binding site of
the antibody accommodates the hapten, with some ambiguity around the area
which corresponds to the point of linkage in the immunogen.
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Since in general a drug and its metabolites will have many simi-
lar structural features, the metabolites will usually be the princi-
pal interfering constituents in an RIA analysis. Thus, in preparing
a conjugate to generate specific antisera, one tries to avoid sites on
the drug which are metabolically reactive, to leave them free‘to in-
fluence the formation of selective antibodies. Also one tries to avoid
covering up structural features which may permit development of
strong affinity binding sites. In addition, one must also consider the
chemistry involved and its difficulty in relation to the expected
benefit.
It is now generally accepted that the principal metabolic alter-
ations in the THC molecule occur in the 8- and 11-positions. Hy-
droxylation may occur in these positions, and oxidation to an 11-
nor-9-carboxy metabolite is also a principal pathway. Metabolites
involving the amyl side chain have also been reported, but it ap-
pears that in quantitative terms these are relatively minor-at least
in humans (2).
Nonselective antisera are also useful, but our interest has been
in the development of assays with specificity for one compound.
Specificity of an assay may be increased by techniques such as dif-
ferential extraction of the desired compound or addition of a
second antibody to tie up the interfering substance (3). However,
these techniques work better if the antiserum has good selectivity
to begin with. We therefore chose to examine immunogens formed
by attaching cannabinoid moieties to proteins through the amyl
side chain, as this would fulfill our requirement of distance from
the principal sites of metabolism.
IMMUNOGEN SYNTHESIS AND ANTISERA TO DELTA-9-THC
For synthetic convenience our initial attempts dealt with the
delta-8 isomer of THC. 5’-Carboxy-delta-8-THC was treated with N-
hydroxysuccinimide and dicyclohexylcarbodiimide to yield an ester
which readily reacted with bovine serum albumin in a mixture of
dioxane and sodium bicarbonate solution to yield the desired im-
munogen containing about 33 residues of delta-8-THC per molecule
of bovine serum albumin (4).
This immunogen was injected into rabbits by a modification of
the intradermal method of Vaitukaitus et al. (4). Reasonable anti-
serum titers were achieved by 7.5 weeks after the first immuniza-
tion and, as we have reported previously, the resulting antisera
showed good selectivity for delta-9-tetrahydrocannabinol vs. its me-
tabolites (4,5).
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Since the antisera produced from the delta-8-immunogen showed
about 2.5 times as great an affinity for delta-8-THC as for delta-9-
THC, it appeared that perhaps even better antisera could be
achieved starting with a delta-9-5’-carboxylic acid hapten. The de-
sired immunogen was synthesized as in the case of the delta-8-
compound. Rabbits were immunized with the resulting conjugate
and antisera which were able to bind delta-9-THC were obtained
(5). As figure 2 shows, the antisera exhibited very low cross-reac-
tions with the 11-nor-9-carboxy metabolite of delta-9-THC. A signifi-
cant cross-reaction with the 11-hydroxy metabolite was observed,
but this compound is present in very low concentrations in blood
after smoking or iv administration (6), so the cross-reaction would
be of concern only after oral administration of delta-9-THC.
Analytical Protocol
Vortex mix 100 µ L plasma with 400 µ L methanol
Let stand, 5-10 min; centrifuge; aliquot
50 µ L aliquot + 400 µ L buffer with radioligand (15,000 cpm)
+ 100 µ L antiserum/buffer
Vortex mix; incubate 4-24 hr at 4°C
Add charcoal/buffer (500  µ L of 1.58% suspension)
Vortex mix; incubate 20 min at 4°C
Centrifuge 15 min at 4°C; decant; count.
FIGURE 2. Protocol for analysis of delta-9-THC or its carboxylic acid metabolite in
plasma.
RADIOLIGANDS
Now let us turn to consideration of the radioligand. Tritium-la-
beled radioligands have the advantage of generally better shelf-life.
They also have an affinity for the antibody essentially equal to
that of the unlabeled compound. On the other hand, iodine-125 has
certain advantages over tritium for use as the radioisotope. These
include the higher theoretical specific activity, resistance to
quenching and ease of measurement. The size of the iodine atom,
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however, makes its introduction into a small molecule such as THC
a problem from the standpoint of binding affinity. Direct substitu-
tion of iodine into such a molecule often inhibits binding to the
antibody and reduces the affinity below that which can give a
useful assay. However, direct introduction of iodine into the 5’-posi-
tion of THC--that is into the position which was linked to the pro-
tein in the immunogen--might allow us to take advantage of the in-
sensitivity of antibody affinity to changes at the position of linkage
in the immunogen. Therefore, 5’-iodo-delta-8-THC was prepared and
submitted to an exchange reaction with iodine-125 sodium iodide.
This procedure led to iodinated THC of moderate specific activity,
ranging from about 8-40 Ci/mmole (4-7). More recently we have
found that displacement of a 5’-tosylate with iodine-125-iodide can
lead to even higher specific activities (7).
ANALYSIS OF DELTA-9-THC IN PLASMA
The above antisera were used to develop an assay for delta-g-
THC in plasma. Initially tritium-labeled delta-8-THC of specific ac-
tivity 60 Ci/mmole (8) was used as the radioligand. Antiserum to
delta-9-THC was used at an initial titer of 1:6000. Standard curves
showed a practical sensitivity of 25 pg. (We define practical sensi-
tivity as the amount which reduces binding of radioligand by 10%.
This is a pragmatic definition, based on experience. Sensitivity
limits based on 2 or 3 standard deviations from blank tubes would
be much lower.)
For plasma analysis we used the procedure shown in figure 2.
Plasma is mixed with methanol (9) and an aliquot of the resulting
supernatant is incubated with the radioligand and antiserum, usu-
ally overnight, at 4°C. Separation is carried out by addition of a
suspension of charcoal in buffer and after centrifugation the super-
natant is counted.
Under these conditions our practical sensitivity limit was 2.5 ng/
ml with either radioligand. When the tritium radioligand was used,
control samples at 8 ng/ml showed a within-assay CV of 5.9% and
a between-assay CV of 6.4%. For 30 ng/ml controls these values
were 6.0 and 5.5%, respectively. Variances (10) are based on 28
assays and 4 tubes were analyzed per sample. Similar results were
seen with the iodinated ligand, but with many fewer analyses.
We have now used both of these ligands in an assay for
tetrahydrocannabinol from plasma. Through the courtesy of Dr.
John Merritt, University of North Carolina School of Medicine, we
obtained some samples from subjects administered delta-9-THC and
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analyzed them using both ligands. The sensitivity in each case ap-
peared to be 2.5 ng/ml. Figure 3 shows the data from a single sub-
ject analyzed using both ligands. Results appear comparable and
this conclusion is supported by figure 4 which shows results from
the analysis of all 62 samples in which either sample gave results
above 2.5 ng/ml. Using tritium as the ordinate, we found a regres-
sion equation with a slope of 1.06 and an intercept of 0.72 ng/ml.
The correlation coefficient was 0.9907.
FIGURE 3. Plasma curve from a subject administered delta-9-THC. The
methodology of figure 2 and either tritium or iodine-125-substituted radioligands
were used.
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FIGURE 4. Comparison of results on analysis of 62 plasma samples for delta-9-THC
with either a tritium or iodine-125-labeled radioligand.
DEVELOPMENT OF SPECIFIC RIA FOR 11-NOR-9-CARBOXY-
DELTA-9-THC
Having demonstrated the utility of our approach to the analysis
of delta-9-THC, we then set out to apply the same principles to the
analysis of various metabolites of delta-9-THC. The l l-nor-9-carbox-
ylic acid (or 11-oic acid) has been shown to be a major metabolite
present in plasma and was chosen as our next target for develop-
ment of an immunoassay. We were reluctant to use a 5’-carboxy
analog of this compound as the hapten to prepare an immunogen,
since this presented the possibility of obtaining a mixture of 5- and
11-linked conjugates. Therefore it was necessary to find some
means of linking through the 5’-position which did not involve a
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carboxylic acid. An aldehyde moiety would appear to be useful in
this respect since it would react with the free amino groups of a
protein such as bovine serum albumin to form an imine and the
latter substance could be reduced with sodium cyanoborohydride to
form a stable alkylamino linkage (figure 5). The synthesis of this
compound, however, proved to be no trivial matter (11).
FIGURE 5. General route to an immunogen containing 11-nor-9-carboxy-delta-8-
THC. Reagents: a) bovine serum albumin (BSA); b) sodium cyanoborohydride.
Again, for reasons similar to those in the THC series, the delta-8-
compound was chosen for synthetic work. In the procedure finally
adopted (figure 6), 5’-bromo-delta-8-THC was treated with tetra-
methyl ammonium acetate to introduce a 5’-acetoxy group. The
phenolic group was protected as its t-butyldimethylsilyl ether, and
the acetoxy group was selectively removed by treatment with lith-
ium aluminum hydride to give the 5’-alcohol which could be oxi-
dized with pyridinium chlorochromate to the 5’-oxo compound. The
aldehyde group was then protected as the ethylene acetal. C-11 was
next converted to an aldehyde with selenium dioxide. Oxidation of
the aldehyde using sodium cyanide and manganese dioxide in
methanol led to the methyl ester of the 9-carboxylic acid. When
this ester was saponified with potassium hydroxide and ethanol,
both the ester and the silyl protecting groups were cleaved. It then
remained only to remove the ethylene acetal to generate the de
sired compound.
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FIGURE 6. Synthesis of ethylene acetal of 5’-oxo-11-nor-9-carboxy-delta-8-THC.
Reagents: a) tetramethylammonium acetate; b) t-butyldimethylchlorosilane; c)
lithium aluminum hydride; d) pyridinium chlorochromate; e) ethylene glycol,
toluenesulfonic acid; f) selenium dioxide; g) sodium cyanide, acetic acid, methanol,
manganese dioxide; h) potassium hydroxide; i) toluenesulfonic acid, acetone.
Tests using a model system with a methyl group at C-9 showed
that under standard acidic conditions used to hydrolyze acetals, the
intermediate aldehyde which formed quickly cyclized by interac-
tion with the reactive phenolic ring. It was therefore necessary to
deactivate the phenolic ring by formation of the phenolic acetate
(figure 7). This compound could then be hydrolyzed under acidic
conditions to give the 5’-oxo compound with the acetate group still
present. Mild basic hydrolytic conditions were found to cleave the
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acetate. However, under the conditions used for coupling to pro-
tein, it was shown that internal cyclization was competitive with
the coupling to protein. Furthermore, the hydrolyzed aldehyde was
unstable and cyclized either on standing or attempted purification
by preparative thin-layer chromatography.
FIGURE 7. Synthesis of immunogen containing 11-nor-9-carboxy-delta-8-THC.
Reagents: a) acetic anhydride, pyridine; b) toluenesulfonic acid, acetone; c) bovine
serum albumin, methanol; d) sodium cyanoborohydride.
The phenolic acetate therefore was allowed to react with bovine
serum albumin in pure anhydrous methanol in the presence of
sodium cyanoboro-hydride (12) and the resulting conjugate was dea-
cetylated by stirring with aqueous methanol and sodium bicarbon-
ate. Differential ultraviolet absorption measurements were then
used to estimate a minimum incorporation of 11 hapten residues
per molecule of protein. Rabbits were immunized with this conju-
gate. An excellent antiserum titer was obtained by 4 months after
initial immunization.
For the radioligand, the methyl ester of 5’-iodo-11-nor-9-carboxy-
delta-8-THC was converted to the free acid by treatment with tri-
methylsilyl iodide followed by hydrolysis with water. Exchange of
the resulting 5’-iodocarboxylic acid with iodine-125 sodium iodide
led to labeled material (figure 8) with a specific activity of about 7.5
Ci/mmole. Using this iodinated radioligand we then examined the
cross-reactions of the anti-serum, which was used at a titer of ap-
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proximately 1:20,000 initial dilution. As shown in figure 9, 11-nor-9-
carboxy-delta-9-THC displaced this radioligand over the range of
20-5000 pg. The practical sensitivity was between 20 and 50 pg. The
carboxylic acid in the delta-9-THC series exhibited only slightly
greater affinity for the antibody than did the 5’-iodo-delta-8 deriva-
tive. 11-Hydroxy-delta-9-THC and delta-9-THC itself exhibited ex-
tremely low cross-reactions, with less than 0.1% the affinity of the
9-carboxy compound. It still remains to be demonstrated that the
antiserum will not cross-react strongly with the very polar acids
which are also formed as metabolites of THC, but based on results
to date it appears that this is an extremely selective antiserum.
FIGURE 8. Synthesis of radioligand for analysis of 11-nor-9-carboxy-delta-9-THC.
Reagents: a) trimethyliodosilane, water; b) iodine-125-NaI, acetone.
ANALYSIS OF 11-NOR-9-CARBOXY-DELTA-9-THC IN PLASMA
We have used this antiserum and radioligand in the analysis of a
series of plasma samples provided to us through the courtesy of
Mr. Owens and Dr. McBay. Conditions for analysis were the same
as for delta-9-THC. Figure 10 shows results for one subject who re-
ceived THC by smoking. The results of this analysis are in excel-
lent qualitative agreement with data obtained by Wall and cowork-
ers (2). THC itself rises rapidly to a maximum after cessation of
smoking and then falls off rapidly. The concentration of the car-
boxylic acid metabolite rises fairly rapidly, reaching a maximum at
around 20-40 minutes and thereafter declining at a slower rate.
Almost identical results were observed in a second subject.
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FIGURE 9. Displacement curves for delta-9-THC, metabolites and iodo compounds.
Antiserum was generated to 11-nor-9-carboxy-delta-8-THC immunogen; radioligand
was iodine-125-5’-iodo-11-nor-9-carboxy-delta-8-THC.
CONCLUSIONS
These studies have demonstrated that linkage of cannabinoid
molecules to protein through the 5’-position of the amyl side chain
leads to the formation of selective antisera. Antisera developed in
this manner can be used for the analysis of plasma samples for
both delta-9-THC and 11-nor-9-carboxy-delta-9-THC, a principal
plasma metabolite. Furthermore, in conjunction with these anti-
sera, the use of a 5’-iodo radioligand has been shown to be both
practical and convenient. As we have previously pointed out, the
general concept of introducing the iodine at the point of linkage ap-
pears to be one which should have widespread utility in radioim-
munoassay work (5). Although the results with the 11-nor-9-car-
boxy-delta-9-THC analysis are at this point somewhat preliminary
and the method requires some further development, it is to our
knowledge the first reported example of a highly specific radioim-
munoassay for this metabolite in plasma. We are now in the proc-
ess of applying these general concepts to the preparation of an
antiserum for 11-hydroxy-delta-9-THC.
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FIGURE 10. Analysis of delta-9-THC and 11-nor-9-carboxy-delta-9-THC in a subject
who smoked a single 9 mg THC cigarette.
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Radioimmunoanalysis of Delta-9-
THC in Blood by Means of an 125I
Tracer
S. M. Owens, A. J. McBay, and H. M. Reisner
A radioimmunoassay or delta-9-THC in plasma, whole
blood, or hemolyzed blood specimens has been presented.
Samples and standards were diluted with methanol and
centrifuged. An aliquot of the supernatant fluid was incu-
bated with RIA buffer, 125I-labeled delta-8-THC and rabbit
anti-THC serum. Solid phase goat anti-rabbit immunoglo-
bulins were added to separate bound from free THC. After
centrifugation the supernatant fluid was aspirated and the
radioactivity of the precipitate was counted in a gamma
counter. The concentration of THC was calculated from a
standard curve using the logit-log transformation of the
average counts of duplicate tubes. The assay had several
advantages. Methanol dilution gave better results than
direct analysis. The 125I-labeled THC had high specific ac-
tivity and could be counted in a gamma counter. The im-
munological separation of anti body-bound THC from free
THC was better than separation techniques using ammoni-
um sulfate and activated charcoal. THC was determined in
0.1 ml of sample with a sensitivity of 1.5 ng/ml in plasma
and 3.0 ng/ml in hemolyzed blood.
INTRODUCTION
There is a need for accurate, sensitive and specific radioimmun-
oassays (RIA) of delta-9-THC (THC) for pharmacological and foren-
sic studies of various biological fluids. The RIA of plasma samples
(1,2) and hemolyzed blood (3) have been reported.
Forensic blood samples are usually grossly hemolyzed. These re
quire a RIA that is not affected by varying degrees of hemolysis.
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An 125I-labeled THC radioligand is needed for this application (4).
The advantages of 125I-THC over 3H- or 14C-labeled THC are that it
is not affected by color quenching during the counting of radioac-
tivity and it can be synthesized at a higher specific activity (5).
THC is a highly lipophilic molecule that adheres to glass and
plastics and binds to various blood products. We found that a criti-
cal step in the RIA of THC was the separation of antibody-bound
radioactivity from other radioactivity. We compared five common
RIA separation methods and found that a solid phase second anti-
body improved the separation.
PREPARATION OF ANTI-THC SERA AND RADIOLIGAND
Delta-8-THC was conjugated to bovine serum albumin by the
method of Cook et al (1). Delta-8-THC was used to make the anti-
gen because delta-9-THC was not available. The concentration of
delta-8-THC in marijuana, if present, is very low compared to the
concentration of delta-9-THC. It therefore will not contribute to the
concentration of delta-9-THC in this analysis.
Four New Zealand white rabbits were each injected with 200 µg
of the antigen in physiological saline emulsified with Freund’s com-
plete adjuvant. All injections were administered subcutaneously
near regional lymph centers. The next four boosts were given every
3 weeks with 100 µg of antigen plus Freund’s complete adjuvant.
Seven months from the start of immunization the rabbits were
boosted with 100 µg of antigen and Freund’s incomplete adjuvant.
The serum was tested for THC binding after the fourth boost and
on all subsequent boosts. The titer was expressed as that dilution of
serum which bound 50% of 85 pg of the radioligand. The assay con-
ditions were those stated in the procedure except that ammonium
sulfate was used to separate bound from free radioactivity. The
serum from the rabbit with the highest titer was chosen for use in
the assay.
The radioligand 5’-iodo-125I-delta-8-THC was synthesized in our
laboratory by the method of Pitt et al (5). The specific activity was
determined to be 250 Ci/mmole by the self-displacement method of
Morris (6).
SPECIFICITY OF ANTISERUM
The cross-reactivity of the antiserum was measured by determin-
ing the concentration of compound that caused 50% displacement
of the radioligand. Since delta-9-THC was the analyte of interest,
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its concentration at 50% displacement was considered as 100%
cross-reactivity. All other compounds were compared to it (table 1).
The assay conditions were those described in the procedure.
TABLE 1. Cross reactivity of various cannabinoids, drugs. and steroids with anti-
delta-8-THC serum. All percent cross reactivities preceded by the symbol for “less
than” gave no indication of crow reactivity at the concentration equivalent to that
percentage.
SAMPLE PREPARATION
THC in absolute ethanol was obtained from the Research Trian-
gle Institute (RTI), Research Triangle Park, NC. Standards and
controls were prepared the day of the analysis by adding THC in
absolute ethanol to plasma or hemolyzed blood sample pools.
Standards were prepared from 1-100 ng/ml. Hemolyzed blood was
made by storing whole blood for at least one month at 4°C with 1%
sodium fluoride as a preservative. All standards, controls, and un-
knowns were treated the same throughout the procedure.
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Sensitivity was increased and interferences were decreased by di-
luting the samples with methanol rather than analyzing the sam-
ples directly. The use of methanol has been reported by Teale et al.
(7).
An aliquot (100 µl) of sample was pipetted into a silanized 10 ×
75 mm glass test tube. The tube was vortexed at low speed while
methanol (500 µl) was added. The tubes were immediately corked.
After 30 minutes the tubes were centrifuged at 1000 × g for 15
minutes. A 100 µl aliquot of the supernatant fluid was used in the
assay. When approximately 10 ng/ml of the radioligand was added
to plasma or hemolyzed blood (n = 10) the percent recovery was 99.3
(%CV= 1.4) and 93.3 (%CV = 4.7) respectively.
RADIOIMMUNOASSAY PROCEDURE
The buffer was tris-NaCl with bovine serum albumin (0.05 M
tris(hydroxymethyl)-aminomethane and 0.15 M NaCl with 0.1%
bovine serum albumin and 0.2% NaN3 adjusted to pH 7.6 with con-
centrated HCl). The radioligand in 50% ethanol was added to the
buffer in a ratio of 40 pg per 500 µl. A 500 µl aliquot of radioligand
in buffer was added to untreated 10 × 75 mm glass test tubes.
Each sample was analyzed in duplicate. An aliquot (100 µl) of the
methanol supernatant fluid was added to appropriate tubes and
vortexed. The anti-THC serum was diluted 1:35,000 with buffer (20-
35% antibody specific binding) and 100 µl was added to all tubes
except control tubes for nonspecific binding and total counts. To
those tubes 100 µl of buffer was added. All tubes were vortexed.
The rack of tubes was sealed in a plastic bag to prevent evapora-
tion and was incubated overnight at 4°C. The next day, 100 µl of
solid phase goat anti-rabbit immunoglobulins (Immunobeads, pre-
pared by Bio-Rad Laboratories, Richmond, CA 94804) were added.
The tubes were vortexed and then refrigerated at 4°C for 1 hour.
The tubes were allowed to warm to room temperature for 1 hour.
They were then centrifuged at 1000 × g for 8 minutes to precipi-
tate antibody-bound radioligand. The supernatant was aspirated
without disturbing the pellet and 2 ml of buffer were added. The
tubes were vortexed and centrifuged as before. The supernatant
fluid was aspirated without disturbing the pellet. This washing re-
duced specific and nonspecific binding approximately 5%. The
tubes were counted in a gamma counter, having an 84.6% counting
efficiency with a 125I source. The concentration of THC in controls
and unknowns was obtained from a standard curve using the logit-
log transformation of the average counts of duplicate tubes.
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COMPARISON OF SEPARATION METHODS
The methods commonly used to separate free from antibody-
bound radioactivity are based on chemical or immunological differ-
ences between free and antibody-bound radioactivity. If the equilib-
rium between the bound and free forms is disturbed a misclassifica-
tion of counts could occur. An ideal method should not affect this
equilibrium. Five radioimmunoassay separation methods were com-
pared. These used polyethylene glycol, Staphylococcus aureus with
protein A, activated charcoal, ammonium sulfate, or solid phase
goat anti-rabbit immunoglobulins (second antibody). The factors
considered in choosing a method were the accuracy of classification
of bound and free counts and the variability of binding with
plasma and hemolyzed blood. The Staphylococcus aureus with pro-
tein A and polyethylene glycol methods were not usable due to
high nonspecific binding and variability from sample to sample.
Ammonium sulfate performed well with plasma even though there
was high nonspecific binding. It could not be used with hemolyzed
blood. The charcoal separation performed well with plasma. With
hemolyzed blood it had variable nonspecific binding with different
samples. Also, a refrigerated centrifuge was needed. The solid
phase second antibody separation gave the most consistent results
with different specimens. The nonspecific binding for plasma was
consistently 0.5% ± 0.1% and for hemolyzed blood it was 1.5% ±
0.2%. Another important feature was that standard curves of
plasma and hemolyzed blood, when assayed in the same RIA, were
almost superimposable (see figure 1). Since plasma had 2.8% great-
er antibody-specific binding of radioligand than hemolyzed blood,
all samples had to be compared to their own zero dose standard,
i.e., plasma unknowns to plasma zero dose standards and hemo-
lyzed blood unknowns to hemolyzed blood zero dose standards.
VALIDATION OF PROCEDURE
To obtain blood containing THC, a smoking study was conducted
under the direction of Dr. Mario Perez-Reyes of the University of
North Carolina Department of Psychiatry. Mexican marijuana
cigarettes containing 1% delta-9-THC (approximately 9 mg) and
other naturally occurring cannabinoids were provided by the Na-
tional Institute on Drug Abuse. Each experienced male and female
volunteer smoked on two separate occasions either a marijuana
cigarette or a placebo. The placebos, which were obtained from
NIDA, were prepared by extracting cannabinoids from marijuana.
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FIGURE 1. Typical RIA logit-log curves for plasma and hemolyzed blood. When
assayed in the same RIA they were almost superimposable. The plasma and
hemolyzed blood curves had slopes of -1.56 and -1.55, y-intercepts of 1.63 and 1.70,
and nonspecific bindings of 0.5% and 1.5%, respectively. Both curves had a
r2=0.999. The percentage of total binding was 2.8% less for hemolyzed blood than
for plasma.
All subjects were asked not to use marijuana for 4 days prior to the
study. Blood samples were collected from an antecubital vein at 0,
5, 10, 15, 20, 30, 45, 60, 90, and 120 minutes after the start of smok-
ing. A portion of the whole blood was preserved with 1% sodium
fluoride. The remaining blood was heparinized and the plasma sep-
arated. All samples were stored in silanized scintillation vials at
- 20 °C until analyzed.
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A total of 50 positive plasma samples from 5 subjects were ana-
lyzed in a double-blind fashion. The results were compared with
time after smoking. This was to determine if the expected concen-
tration vs. time curve would be produced (see figure 2). The bipha-
sic curve that was produced was similar to that of Wall et al (8).
FIGURE 2. Five subjects smoked Mexican marijuana cigarettes that contained
approximately 9 mg of THC. It took from 7.5 to 13 minutes to finish the cigarettes.
The concentration vs. time curves were all biphasic and similar for each subject.
As further validation, 31 positive and 21 negative plasma sam-
ples from the smoking study were analyzed in double-blind fashion
at RTI by the delta-9-THC RIA of Dr. C. E. Cook and by our proce-
dure (see figure 3). The correlation coefficient was 0.971. All nega-
tive samples were correctly identified by both laboratories.
The usual means of determining sensitivity of a RIA is to evalu-
ate statistically the counting variances of zero dose standards (9).
By this criterion, the sensitivity for THC in plasma and hemolyzed
40 OWENS, McBAY, AND REISNER
FIGURE 3. Comparison of 31 positive samples analyzed in a double-blind fashion at
RTI by a THC RIA and by our THC RIA. The correlation coefficient was 0.971.
blood specimens would be less than 1 ng/ml. The analysis of pre-
sumed negative samples proved to be a more rigid criterion for sen-
sitivity estimation.
The sensitivity was determined by comparing the calculated con-
centrations of all negative samples with the zero dose standards.
Negative blood samples were obtained from subjects smoking place-
bos and from 10 nonusers of marijuana. Altogether 61 negative
plasmas and 16 negative hemolyzed bloods from 16 different sub
jects were analyzed. No plasma was calculated greater than 1.0 ng/
ml and no hemolyzed blood was calculated greater than 2.5 ng/ml.
To assure no false positives, the least detectable concentration was
arbitrarily set at 1.5 ng/ml in plasma and 3.0 ng/ml in hemolyzed
blood.
RADIOIMMUNOANALYSIS OF DELTA-9-THC IN BLOOD 41
We are presently trying to confirm if all samples from the place-
bo smoking study are THC-free. Some had significantly higher con-
centrations than the concentrations found in nonusers of marijua-
na. Since individuals in the smoking study were marijuana users,
the low concentrations of THC found in some samples may repre-
sent low residual concentrations of the drug.
The intra-assay reproducibility was determined using plasma or
hemolyzed blood spiked with THC (see table 2). The interassay pre-
cision for plasma samples was determined by using samples from
the smoking study (see table 3). The hemolyzed blood interassay
precision is being determined.
TABLE 2. Reproducibility of the assay of known quantities of THC. THC was added
to a plasma or hemolyzed blood sample pool. The THC concentration was calculated
from standard curves which were similar to figure 1.
TABLE 3. The interassay precision was determined using plasma samples from a
marijuana smoking study. The replicates were analyzed in spearate assays over a 3-
week period.
CONCLUSIONS
The concentration of THC after smoking can be accurately deter-
mined in various biological fluids by this RIA, using an 125I tracer
and a specific separation method. This assay will be of use in foren-
sic and pharmacological studies.
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Significant Developments in
Radioimmune Methods Applied to
THC and its 9-Substituted
Metabolites
J. R. Soares, J. D. Grant, and S. J. Gross
Novel RIA’s have been developed for marijuana detection.
Modified simple techniques measure the “acute” metabo-
lites in minute saliva, breath, and dried blood samples?
Solid purified antibody matches the sensitivity and yields
sensitivity values identical to liquid assays. The importance
of the polar 9-substituted metabolites (9SM) of THC in
acute users is shown by time course data that indicate their
levels remain high in the critical post-intoxication period
when -THC clears from the blood. Therefore a single-tube
assay using solid-phase reagents was constructed to quanti-
tate simultaneously   THC and 9SM. When -THC values
are low or questionable in subject samples, 9SM would
appear useful to confirm or refute acute marijuana use.
INTRODUCTION
The evolution of radioimmunoassay (RIA) techniques has con-
firmed our original concept (1) that desirable specificity depends on
sterically free chemical functions in the hapten and marker moie-
ties.
These pr inciples  have a l lowed the development  of
tetrahydrocannabinol (THC) and polar g-substituted THC metabo-
lite (9SM) assays requiring a single incubation of 20 µl samples of
serum or blood (hemolyzed). These sensitive assays (5 ng/ml) have
routine clinical applicability. For example, THC dosage for antie-
metic effects can effectively be monitored by serum concentration.
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Furthermore, such determinations will add substantially to clinical
epidemiologic and behavioral assessments. Given a high avidity
antibody, the assay is flexible and can encompass a broad spectrum
of liquids and solids. Since there are obvious forensic applications,
the existing methodology has been extended to breath.
Conventional RIA procedures require select reagents and critical
steps mainly to separate free radioligand from that bound to anti-
body. This can be accomplished by “pour out” or “dipstick” tech-
niques utilizing newly developed solid matrices containing cova-
lently bound antibody or hapten. These materials can now be used
to measure two (or more) different entities simultaneously in a
single container.
MATERIAL AND METHODS
Subjects
Fifteen adult male volunteers were recruited. Their marijuana
habits ranged from light (<1/month) to heavy (>3/day). They
were asked to refrain from private use of cannabis for 24 hours
prior to testing and the baseline (pre-smoke) negativity of their
samples (blood and breath) verified by RIA. Volunteers were al-
lowed 15 minutes to complete a single marijuana cigarette contain-
ing THC equivalent to approximately 200 µg   THC per kg body
weight of subject. Blood and breath were collected at various inter-
vals up to 6 hours after smoking. Serum was obtained by centrifu-
gation of samples in red top vacutainer tubes. Five uninterrupted
breaths were passed over a borosilicate solid matrix. Cannabinoids
were recovered by elution with ethanol, reconstituted in buffer and
tested for -THC and 9SM content by liquid phase methods (de-
scribed below).
Haptens and Antigens
The 2-(4’carboxyphenylazo) derivatives of THC (Azo-THC),  11-
hydroxy- -THC (Azo-11-OH) and cannabinol (Azo-CBN) were cova-
lently coupled to polymers for immunization (2) and affinity chro-
matography (3).
Antisera
Texas bush goats were immunized with Keyhole Limpet Hemo-
cyanin conjugates of Azo-THC and Azo-11-OH as previously de-
scribed (2). Sera harvested by plasmapheresis were tested as fol-
lows.
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Titer was defined as the dilution at which 0.1 ml of antiserum
binds 40% of added 3H- -THC (40,000 cpm). Cross reactivities were
calculated from standard curves and expressed as -THC/canna-
binoid mass ratio at 50% inhibition ( × 100%).
Diluted THC-specific antiserum was used directly in standard
liquid-phase assay. 9SM antibodies isolated by affinity chromato-
graphy were coupled to an insoluble matrix for solid-phase meth-
ods.
lmmunosorbant
The Azo-CBN carboxyl (50 µmoles) was converted to an active
ester by isobutyl chloroformate (60 µmoles) and added to a 10%
suspension of aminoalkyl agarose (Affi-Gel 102, BioRad, 35.1
µmoles of alkylamine) in dioxane. The immunosorbant (AZO-CBN-S)
was washed with dry dioxane (1L) to remove uncoupled hapten,
and stored in distilled water.
Affinity Chromatography
Saturated ammonium sulfate was added to Azo-11-OH antisera to
a final concentration of 33% and the precipitate (crude IgG) fur-
ther purified by passage through QAE Sephadex (QAE IgG). Anti-
body dilutions were concentrated (10 ng/ml) and 10 ml aliquots
were incubated with immunosorbant to remove all antibody from
the supernate. Azo-CBN-S was washed with PBS (0.01 M phosphate
buffer, pH 6.9, 0.9% sodium chloride) until free of nonspecific pro-
tein (O.D. < .005). There was a final wash with 1 M lithium bromide
(100 ml). Clean immunosorbant was pipetted into glass columns (1.2
× 15 cm). Elution with 0.09 M hydrochloric acid (30 ml) removed
specific antibody. The eluate was dialyzed against distilled water
(12 hours at 4°C) and phosphate buffer (24 hours at 4°C).
Purified antibody was concentrated with sucrose and concentra-
tions calculated spectrophotometrically (280 nm). Final titer was
compared with parent solutions to document recovery of activity.
Matrix Antibody Conjugates
Antibody fractions of varying purity were coupled to a polyfunc-
tional acrylate. Active polymer fractions (33 mg) were reacted with
400 µg per ml antibody (3.0 ml). Uncoupled IgG was removed with
PBS. Binding efficiency of immunosorbant-purified antibody-matrix
conjugate (Ab-C) was compared with IgG-polymer controls (non-
immune IgG, crude IgG and QAE IgG fraction). Solid-phase rea-
gents (30% suspension in PBS) were stored at 3°C.
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Liquid-Phase Radioimmunoassays
The following cannabinoids were obtained from the National In-
stitute on Drug Abuse (NIDA): -THC, - -THC, 11-hydroxy
THC, 11-nor- -THC-9-carboxylic acid, cannabinol, cannabidiol, and
3H- -THC (50.3 Ci/mM).
Standard inhibition curves were constructed from non-user sam-
ples containing known amounts of - THC. Serum (50 µl) was incu-
bated (16 hours, 4°C) with 0.1 ml antiserum (diluted to bind 40% of
added marker in the absence of unlabeled THC) and 188 pg (40,000
cpm) of 3H- -THC. Free and antibody-bound radioligands were sep-
arated using 0.5 ml dextran-coated charcoal suspension (50 gm
Norit A charcoal and 5 gm dextran T-70 in 1.0 L PBS) chilled at
4°C by refrigeration. Antibody-bound 3H- -THC was counted in a
Beckman LS-250 Beta counter after decanting supernates into scin-
tillation vials containing 10 ml of Aquasol (New England Nuclear).
Logit transformation (4) was employed to construct standard
curves and to calculate -THC concentrations of unknown samples
using a Wang 2200 computer.
Solid-Phase 9SM RIA
Serum standards were prepared from pooled marijuana negative
serum. Stock solutions of 11-nor- -THC-9-carboxylic acid in 50%
ethanol (0.01 mg/ml) were diluted 1/100 with serum to give a final
concentration of 100 ng/ml. This was serially diluted in serum for
standard curves which were included in each assay by transferring
aliquots (20 µl) from a sequence of cannabinoid concentrations into
10 × 75 mm borosilicate glass tubes in duplicate. Unknown sam-
ples (20 µl) were assayed identically.
Ab-C (10 µl) and 3H- -THC (30,000 cpm/0.6 ml PBS, 0.1% albu-
min) were added and the tubes incubated for 12 hours at 4°C with
intermittent shaking. PBS (1.0 ml) was added, and the tubes vor-
texed. After centrifugation (4,000 rpm, 10 minutes), supernates
were discarded, and the percentage of 3H- -THC bound to antibody
calculated by counting the matrix directly in scintillation fluid.
Log-logit standard curves were used to estimate unknown 9SM con-
centrations,
Dual-Metabolite RIA
The foregoing method was modified to assay -THC and 9SM si-
multaneously in a single tube. -THC and 9SM serum standards
were added to separate sets of 10 × 75 mm borosilicate glass tubes
in duplicate. 3H -THC (30,000 cpm/0.l ml), Ab-C (10 µl) and solu-
ble -THC specific antibody (0.5 ml) were added to each set and
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the reagents incubated (12 hours, 4°C) with intermittent shaking.
The tubes were centrifuged and the percent of label bound to 9SM
antibody determined by measuring matrix counts. 3H- -THC
bound to -THC specific antibody was measured in the supernate.
Unknown samples (20 µl) were assayed identically, and  -THC
and 9SM concentrations estimated from liquid ( -THC) and solid
(9SM) phase standard curves.
RESULTS
Antisera Specificities
Cross-reactivities are summarized in table 1. 11-Hydroxy -THC,
11-nor- THC-9-carboxylic acid and -THC are equally recognized
by the 9SM antibody. The non-homologous radioligand (3H- -THC)
contributed to this spectrum. -THC antiserum has far greater
specificity, the cross-reactivities for 11-hydroxy- -THC and 11-nor-
-THC-9-carboxylic acid being 26% and 0.5% respectively.
TABLE 1. Percent Crossreactivities*
Compound 9SM
Antiserum
-THC 100.0 100.0
-THC 98.2 96.5
11-hydroxy- -THC 97.6 26.0
11-nor- -THC-9-carboxylic acid 96.5 0.5
Cannabinol 15.5 22.0
Cannabidiol 0.1 0.15
THC/cannabinoid ratio at 50% inhibition (x 100%).
Cannabinoid Blood Levels
Pre-intoxication levels of 9SM and -THC were negative in sera
from all 15 volunteers. Initial samples taken 15 minutes after com-
pletion of smoking showed -THC concentrations between 9 and
42 ng/ml. Thereafter, levels rapidly decreased, becoming undetecta-
ble at 2 l/4 to 3 l/4 hours. 9SM levels were vastly higher (20-198
ng/ml) than corresponding -THC values. The persistence of meta-
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bolites was longer than -THC in all subjects but varied with their
individual habits. For example, in all three subjects who used mari-
juana heavily (>3 times/day) 9SM levels remained elevated (>20
ng/ml) up to 6 hours after marijuana inhalation (figure 1). 9SM re-
turned to baseline (0) in two subjects whose sera were obtained at
24 hours. Alternatively, 9SM decreased to the level of assay sensi-
tivity (5 ng/ml) in all moderate smokers (1-4 times/week) by 6 1/2
hours. Finally, two light smokers’ (<1 time/month) sera contained
no measurable 9SM 3 1/4 hours following acute exposure.
FIGURE 1. Serum levels of THC 9-polar metabolite in individuals who differ in
degree of marijuana use. Levels of 9SM were determined at various intervals after
subjects smoked one marijuana cigarette containing 200 µg THC/Kg body weight.
In all cases, 9SM cleared more slowly from the blood than
THC. Indeed, the mean 9SM/ THC ratio for these subjects in-
creased from 2.9 at 15 minutes to 5.7 at 2 1/2 hours.
Breath
Cannabinoids were measured in trapped breath from ten of the
above volunteers after smoking a single marijuana cigarette. Both
-THC and 9SM were detected immediately upon completion of
smoking (0 time). Levels of THC between 10 and 56 ng/sample
were measured at 15 minutes after smoking and were detectable to
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1 hour. Higher concentrations of 9SM were noted (table 2) with
maximum values (50-123 ng/sample) observed at 15 minutes. Sig-
nificant amounts of 9SM were detected up to 2 1/2 hours.
TABLE 2. THC Metabolites in Breath at Various Intervals after
Smoking a Single Marijuana Cigarette (200 µg THC/Kg
of body weight)
Time* 9SM levels in trapped breath**
Post-intoxication
(minutes) Subjects
RR EP JT DG
*Zero time signifies completion of smoke.
**Trapped breath was analyzed by liquid-phase methods using spiked-buffer
standards and 9SM level expressed as ng recovered per sample.
Solid-Phase 9SM Assay
Standard Curves
Ab-C and QAE IgG-C standard curves are compared in figure 2.
Six replicate assays were used to construct the Ab-C curve. Log-
logit transformation of this data yielded a linear response to 9SM
in the 2-50 ng/ml range. The uniformly low coefficients of variation
for each standard documented precision throughout the response
curve. Assay sensitivity (2 ng/ml) was defined as the point on the
standard curve greater by 2 standard deviations than 0.0 ng/ml.
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FIGURE 2. Solid-phase 9SM standard curves. THC-negative serum samples spiked
with 9SM were added to tubes containing antibody-matrix conjugate and 3H- THC.
Matrix was counted after incubation with (B) and without (B0) hapten. Log-logit
transformations of mean values from six replicate assays were used to construct
standard curves. The coefficient of variation for each point of the linear Ab-C
standard curve is in parenthesis. The flattening of the QAE IgG-C curve at high
9SM concentrations is indicative of high capacity nonspecific binding.
In contrast, QAE IgG-C standard curves were nonlinear. This oc-
curred because less antibody IgG was available for covalent linkage
per unit volume of matrix in competition with other proteins in
crude antibody fractions. Thus, larger aliquots of QAE 1gG-C (100
µl) than Ab-C (10 µl) were required to bind sufficient 3H- THC
(figure 3). Resultant nonspecific binding caused extreme distortion
of the QAE IgG-C standard curve resulting in loss of specificity and
sensitivity.
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FIGURE 3. SH- -THC binding to polyacrylate antibody conjugates. Binding of 3H-
-THC to insolubilized antibody fractions of various purity. Small aliquots of
immunosorbant-purified material (20 µl/30% v/v suspension) binds 3H- THC well.
The excessive amounts of QAE Sephadex antibody conjugate (100 µ1/30% v/v
suspension) needed for equivalent binding of 3H- -THC results in 30% nonspecific
binding.
Precision
Intra-assay precision was measured by analysis of aliquots of
single samples in the same assay. A mean coefficient of variation of
14% was obtained with four volunteers’ sera assayed in duplicate.
Inter-assay precision was evaluated by analysis of six samples in
two separate assays. The coefficient of variation for these results
was 17%.
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Solid-Phase Dual-Metabolite Assay
Simultaneous quantitation of both THC and 9SM in a single
assay tube was done by partitioning antibody into solid (9SM) and
liquid ( -THC) phases. Soluble  -THC antibody measured -THC.
The 9SM were measured by homologous insolubilized antibody.
Accuracy
Accuracy was assessed by analysis of cannabinoid negative
serum to which varying amounts of -THC, 9SM, or both had been
added (table 3). Observed (O) and expected (E) values were com-
pared to calculate the percent recovery from spiked serum (O/E ×
100%). 9SM recovery was excellent (92-120%) for concentrations
ranging from 0-50 ng/ml except when -THC levels were high
(> 10 ng/ml). In this situation excess -   THC displaces significant
amounts of 3H- -THC from its homologous antibody. A portion of
this label then binds to 9SM-specific antibody, resulting in slight
underestimation of 9SM (70-84% recovery). Importantly, -THC
values were accurately measured irrespective of 9SM content of
serum (92-110%).
TABLE 3. Recovery of 9SM and - THC Added to Cannabinoid
Negative Serum Measured by Simultaneous RIA
Cannabinoids added Cannabinoids measured Recovery (%)
(ng/ml) (ng/ml)
Aliquots of serum were spiked with varying amounts of -THC, 9SM, or both.
These were assayed in a single test tube by solid-phase methods.
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Subject Samples
9SM and   -THC were measured by this method in the sera of
volunteer smokers. Liquid-phase assay was used to corroborate ac-
curacy. Results from six subjects illustrate several important fea-
tures (table 4). 9SM levels were precisely quantitated and were 4-6
times higher than corresponding -THC values. Additionally, in
certain subjects (3 and 5) 9SM were useful in confirming a margin-
al THC. Furthermore, the negative status of one control subject
(4) with a reported THC of 2.3 ng/ml was affirmed by the ab-
sence of measurable 9SM.
TABLE 4. Sera Assayed for 9SM and -THC by Simultaneous RIA
Subject Standard RIA Results Single Tube Assay Results
(ng/ml) (ng/ml)
1 25 26 24 32
2 6 29 5 22
3 3 12.5 4.5 16
4 2.3 3.5 0
5 7.0 36.3 10 45
6 0 0 0 0
Marijuana metabolites were measured In subjects’ sera within three hours of
acute exposure. Standard liquid assay was used to assess the accuracy of simul-
taneous metabolite measurements.
DISCUSSION
The early liquid-phase RIA is a flexible technique which has
been effectively employed for -THC and metabolite meas-
urements in minute volumes of body fluids using samples ranging
from clear serum to hemolyzed blood. However, expertise in pipet-
ting small volumes containing high concentrations of troublesome
macromolecules (5) is required to quantitate low nanogram/ml con-
centrations. In addition, physical (charcoal, ammonium sulfate) or
immunologic (second antibody) separation steps require critical
timing and may introduce dilution, “stripping” and nonspecific
binding errors. These limitations of liquid-phase RIA’s have stimu-
lated development of solid-phase techniques in many laboratories
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here and abroad. An antibody-coupled solid matrix simplifies and
can even eliminate the steps necessary to separate free from bound
hapten. Finally, since the solid phase is counted, water and macro-
molecule quenching of scintillant is avoided.
Reactive solid polymers can selectively remove and concentrate
desired hapten from a dilute body fluid containing a great mixture
of ingredients. Thus, such a matrix permits the collection and sub
sequent measurement of cannabinoids from breath samples.
It should be noted in this context that studies in which tritiated
-THC was administered intravenously (Mario Perez-Reyes, per-
sonal communication), no radioactivity was detected in saliva. If
the present findings reflect metabolic processes at the lung surface,
cannabinoid measurement in breath has potential significance.
The newer methods employing solids available in geometric
forms ranging from regular tubes to amorphous beads lead to si-
multaneous serum THC and 9SM measurements in a single con-
tainer. This has potential merit in gauging marijuana impairment,
particularly when -THC concentration is marginal. Long-term
stability evaluations of purified antibody and the other solid rea-
gents are now required. Polyphase supports will eventually encom-
pass a large variety of molecules currently assayed by qualified
technicians in hospital and reference laboratories. The new genera-
tion of methods will simplify their tasks and perhaps allow quanti-
fication in the low nanogram/ml range by less experienced individ-
uals.
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A high-performance liquid chromatography-radioimmuno-
assay met od for the measurement of cannabinoids inh
plasma and urine is described. The experimental procedure
consists of chromatraphing a plasma extract or hydro-
lysed urine sample by high-performance liquid chromato-
graphy and quantifying the elutin cross-reacting canna-
binoids with radioimmunoassay. The concentrations of
tetrahydrocannabinol (THC), cannabinol, mono-hydroxylat-
ed metabolites, di-hydroxylated metabolites, THC-11-oic
acid, and -THC-11-oic acid ester glucuronide may be
measured by this technique.
INTRODUCTION
Radioimmunoassays (RIA) for the analysis of cannabinoids in
human body fluids have been described (1-5) and have a number of
advantages compared with other analytical techniques. Biological
fluids may be analysed without pretreatment, the sensitivity of the
method is high, large numbers of samples may be analysed at the
same time and the selectivity of the antiserum for cannabinoids
gives the assay a high degree of specificity. However, each anti-
serum cross-reacts with different cannabinoids to different extents
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and these cross-reactions may be further changed by altering the
assay conditions, radioligand, etc. (6). An antiserum for use in a
RIA can be produced such that it  may be specific for
tetrahydrocannabinol (THC). Thus, THC levels in plasma may be
measured directly with the use of this antiserum, even though
other cannabinoids or THC metabolites may be present. However,
if the 11-nor- THC-9-carboxylic acid (THC-11-oic acid) is to be
measured in urine, then a separate antiserum, and hopefully one
specific to the acid metabolite and no other, must be prepared for
use in another RIA (7).
An alternative approach is to produce an antiserum which cross-
reacts with a number of cannabinoids including THC and some of
its metabolites. This antiserum may then be used to assay plasma
or urine, but the levels found can only be expressed as cross-react-
ing cannabinoids, since the analytical results are the sum of all the
cross-reacting cannabinoids present in the sample (8). Although
only one RIA is now needed for any biological fluid to be assayed,
the ease of analysis has been exchanged for lack of specificity.
Other methods for the assay of cannabinoids in biological fluids
have been developed, but nearly all require lengthy analysis times,
due partly to the extensive purification procedures required prior
to the instrumental analysis. The use of chromatographic methods
has aided analyses because of the separating power of the tech-
niques, but detection problems have always been evident. Various
devices have been used to increase the selectivity of ultra-violet
(UV) detectors in high-performance liquid chromatographic (HPLC)
analyses, e.g., by the use of a Sephadex column clean-up prior to
HPLC (9) or by the use of simultaneous dual wavelength UV detec-
tion (10). However, the great separating power of HPLC has con-
stantly been hindered by the lack of a specific detector. The use of
HPLC as a clean-up procedure before the use of another analytical
technique has obvious advantages, and methods involving mass
spectrometry (MS) (11), gas chromatography (GC) using electron
capture detection (12), and liquid scintillation counting for radiola-
belled metabolites (13) have been used.
The combination of RIA with HPLC has obvious advantages. The
drawback of the lack of a sensitive and specific detector for canna-
binoids in HPLC can be overcome by the use of a radioimmunoas-
say, and the lack of complete specificity of an antiserum can be
overcome by the prior use of HPLC. Thus, cross-reacting compo-
nents can be separated by the HPLC system, and by collecting frac-
tions at the end of the column the individual cannabinoids can be
quantified. This procedure has been used for the quantification of
THC and its metabolites in human plasma (14) and also for the
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analysis of THC metabolites in human urine (15). Plasma levels of
THC obtained by the HPLC-RIA method have also been compared
with those obtained by a GGMS procedure. The HPLC-RIA meth-
ods are presented below, together with a discussion on the advan-
tages of the combined technique for use in forensic toxicology.
COLLECTION OF SAMPLES
Volunteers smoked tobacco cigarettes impregnated with either 10
or 8 mg of THC over a lo-minute period. Blood samples (10 ml)
were taken at timed intervals after the subject had finished smok-
ing. Anticoagulant (potassium EDTA, 10 mg) was added to the
blood, which was centrifuged to separate the plasma. Urine sam-
ples from the same subjects were collected in silanised glass con-
tainers during the 24-hour period after smoking. Control urine
samples were obtained from volunteers with no experience of can-
nabis use. All samples were stored at -20°C until analysis.
RADIOIMMUNOASSAY
Antiserum (133Y/22/5) for the assay was obtained from Dr. J. D.
Teale, Department of Biochemistry, University of Surrey, Great
Britain. -THC and other cannabinoid compounds were provided
by the National Institute on Drug Abuse, Rockville, Maryland,
U.S.A. (G-3H)-THC was purchased from the Radiochemical
Centre, Amersham, Great Britain, polyvinylpyrrolidone-40 and
charcoal (Norit A) from Sigma, St. Louis, Missouri, U.S.A., Dextran
T70 from Pharmacia, Uppsala, Sweden, and methanol (AnalaR)
and all other chemicals and solvents were obtained from BDH,
Poole, Great Britain. An Intertechnique SL30 was used for liquid
scintillation counting.
Antiserum (133Y/22/5) was stored as aliquots in buffer (0.1M
phosphate buffer pH 7.5, containing 0.2 percent
polyvinylpyrrolidone-40) at -20°C and diluted to 1:300 before use.
Solutions of THC used to calibrate the assay were made up in
aqueous methanol (50 percent v/v) at concentrations ranging from
500 pg/ml to 50 ng/ml and stored at -20°C. (3H)-THC (12 Ci/
mmole) was also stored at -20°C at a concentration of 0.25 µCi/ml
in aqueous methanol (50 percent v/v, pH 8.6) ready for use.
The plasma sample to be assayed was mixed with three volumes
of methanol, vortexed and allowed to stand for 30 min. It was then
centrifuged and the supernatant added directly to the assay tubes.
Normal human plasma similarly treated was used in the total,
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nonspecific binding and zero binding tubes and for assay dilutions.
The plasma extract (100 µl) was mixed with the radiolabel (50 µl),
50 percent v/v methanol (100 µl), and antiserum (100 µl). The final
assay volume was made up to 600 µl with buffer and methanol to
give a final methanol concentration of 25 percent v/v. After
mixing, the solutions were left to stand at room temperature for 1
hour. Dextran-coated charcoal (200 µl, pH 7.4) was added, the tubes
were centrifuged, and after 2 minutes contact time the supernatant
(500 µl) from each tube was counted. Urine samples were treated in
a similar manner. All analyses were performed in duplicate.
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-
RADIOIMMUNOASSAY
A constant-flow pump (M-6000A Waters Associates, Milford, Mas-
sachusetts, U.S.A.) was used to deliver a methanol-water eluent to
a stainless-steel HPLC column (10 cm × 4.6 mm i.d.) slurry-packed
with Spherisorb-5-ODS (Phase Separations, Flintshire, Great Brit-
ain). Samples were introduced into the HPLC column with a six-
port injection valve (Spectroscopy Accessory, Sidcup, Great Britain)
fitted with a 10 ml injection loop. Column eluate was either moni-
tored with an ultraviolet (UV) detector at 280 nm (Cecil CE212) or
collected with a Struers Samplomat fraction collector (Camlab,
Cambridge, Great Britain). A freezedrier (Model SB4, Chemlabora-
tory Instruments, Ilford, Great Britain) was used to remove sol-
vents.
Plasma (0.2-1 ml) was mixed with three volumes of methanol,
vortexed, left to stand for 30 min and centrifuged. The supernatant
was removed, the residue mixed with methanol and the sample
again centrifuged. Water was added to the combined supernatants
to give a methanol concentration of 50 percent (v/v). Urine (0.1-3
ml) was mixed with methanol and a methanol-water (50:50) buffer
(0.lM acetic acid adjusted to pH 5.5 with sodium hydroxide) to give
a final volume of 6 ml and a methanol concentration of 50 percent
v/v. Metabolite conjugates in urine were hydrolysed by adding an
equal volume of methanolic sodium hydroxide (1M) to the urine,
evacuating the vessel to remove oxygen and leaving at room tem-
perature for 30 minutes. Sufficient acetic acid was then added to
give a pH of 5.6 and the volume was made up to 6 ml with metha-
nol-water (50:50) buffer (pH 5.5).
Plasma extract and unhydrolysed or hydrolysed urine samples
treated as above were then injected onto the HPLC column with
the loop injector. A stepped solvent elution programme was used:
60 MOFFAT, WILLIAMS, AND KING
10 ml of methanol-water (50:50), 10 ml of methanol-water
(62.5:37.5), 20 ml of methanol-water (72.5:27.5) at a flow rate of 1
ml/min. Eluate fractions were taken every 30 seconds and were
lyophilised. The freezedrier was flushed with argon before and
after drying to prevent atmospheric oxidation of sensitive metabo-
lites. A solution of (3H)-THC (0.025 µCi in 500 µl of a mixture of
methanoldiluent buffer, 30:70) was added to each of the dried tubes
with a solution of antiserum in diluent buffer (100 µl of 1:300 anti-
serum solution). The nonspecific binding tubes received diluent
buffer in place of antiserum solution. The subsequent RIA proce-
dure was the same as that described above.
Cannabinoid retention volumes were determined by monitoring
the eluate with either RIA for cross-reacting compounds, or UV ab-
sorption (280 nm) for non-cross-reacting compounds. UV detection
required µg quantities compared with the ng quantities needed for
RIA detection.
GAS CHROMATOGRAPHY-MASS SPECTROMETRY
The internal standard (5’,5’,5’-2H3- THC, 10 ng) in methanol was
added to the plasma sample (1 ml) and the mixture extracted with
methanol as above. The plasma extract was chromatographed
using the HPLC column above and an eluent of methanol-water
(67.5:32.5). The THC fraction (retention volume 20 ml) was collect-
ed, lyophilised and the residue dissolved in hexane. Injections were
made into a Pye 104 GC using a 3 percent OV-17 column (0.3 m ×
2 mm i.d., Gas Chrom Q, 80-100 mesh) at 190°C when THC had a
retention time of 4 min with a helium flow rate of 20 ml/min. The
VG Micromass 16F mass spectrometer was used in the multiple ion
detection mode tuned to ions of m/z 299 and 314 for THC and 302
and 317 for the tri-deuterated THC. Plasma concentrations of THC
were calculated from the ratio of ion intensities for THC and inter-
nal standard using a previously prepared calibration graph.
RESULTS AND DISCUSSION
The antiserum used in this study did not cross-react with 44 non-
cannabinoid drugs at concentrations of 400 µg/ml in plasma and is
therefore very selective for cannabinoids. It does, however, cross-
react with a number of cannabinoids (table 1). Minor modifications
to the molecule at the 8, 9, or 11 positions do not alter the cross-
reactivity significantly, so the antiserum can be used to measure
THC, or any of the metabolites formed by changes at the 8, 9, or 11
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positions, in either plasma or urine. The level of cross-reaction nor-
mally obtained for blank plasma is in the region of 4 ng/ml, with
only exceptional cases being as high as 9 ng/ml. The supernatant
serum from a post mortem specimen of blood which is grossly hae-
molysed gives similar values, so that a suitable cut-off level for a
positive result is about 5 ng/ml. Urine samples have a much lower
cut-off level (1 ng/ml) and only in exceptional circumstances, e.g., if
a large amount of an antibacterial inorganic preservative is added,
may the level be above this.
TABLE 1. Cross-Reactivity of THC Metabolites and Analogues
in the Radioimmunoassay
Cannabinoid Amount requird for 50%
depression of binding (ng)
The plasma levels of cannabinoids, determined by direct RIA, for
volunteers who smoked 10 mg THC were between 70 and 6 ng/ml
over the 2-hour period examined. Table 2 gives the results for one
smoker who was a cannabis user and had THC metabolites in his
plasma before the experiment started.
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TABLE 2. Plasma Concentrations of -THC in a Subject
Who Had Smoked 10 mg -THC Measured by
RIA, HPLC-RIA and GC-MS
Time after Plasma concentration of -THC (ng/ml)
smoking
(min) Direct RIA* GC-MS HPLC-RIA
* These values included contributions from THC metabolites.
* * The subject was a cannabis user and this level represents
the level of cannabinoids present n his plasma before the
experiment started.
The results obtained by the GC-MS method indicate that no THC
was present at the start of the experiment and a high level (55 ng/
ml) was obtained 2 minutes after stopping smoking. The level
gradually fell to 2 ng/ml over the 2-hour period. The direct RIA re-
sults, however, do not show the same fall, since at 2 hours the
plasma still had a level of 48 ng/ml cross-reacting cannabinoids.
Much of the THC had left the plasma by this time, but there was
still an appreciable level of its metabolites cross-reacting in the
RIA.
The HPLC-RIA method can separate and individually quantify
these cross-reacting metabolites, and figure 1 shows a HPLC-RIA
chromatogram of a plasma sample taken 13 minutes after the vol-
unteer had finished smoking a cigarette containing THC. Although
there was still some THC present, there were also cross-reacting
compounds eluting at the retention volumes of the mono- and di-
hydroxylated metabolites, with the greatest contribution coming
from the compounds with the elution volume 10.0 ml, which corre-
spond to the THC-ll-oic acid and its ester glucuronide.
The retention volumes of THC, its metabolites, and other canna-
binoids are given in table 3. The quantity of any of the compounds
may be obtained by integrating the individual points on the peak
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FIGURE 1. HPLC-RIA chromatogram of a plasma sample from a subject taken 13
minutes after smoking 10mg THC. The retention volumes of THC, CBN, the
mono-hydroxylated metabolites and di-hydroxylated metabolites are marked.
to give the total contribution for that compound. Thus, when the
HPLC-RIA method is used to quantify the THC in the plasma sam-
ples, very good agreement with the CC-MS results is obtained
(table 2), since both methods are now measuring the same com-
pound (THC) without any other cannabinoids interfering in the
assay.
The detection of cannabis smoking by an individual who habit-
ually uses cannabis is very much easier when urine is analysed by
RIA because the levels of cross-reacting cannabinoids are much
higher than in plasma. For example, a single smoked dose of 10 mg
THC still gave levels of 49 ng/ml cross-reacting cannabinoids in the
urine 24 hours after smoking (table 4), although it must be noted
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TABLE 3. Retention Volumes of Cannabinoids by
Reversed-Phase HPLC
Cannabinoid Retention volume (ml)
TABLE 4. Urine Concentrations of THC Metabolites In a Subject
Who Had Smoked 10 mg THC Measured by Radiolmmunoassay
Time after RIA cross- Urine volume Total cross-
smoking (hr) reaction (ng/ml) (ml) reacting material
(µg/hr)
*The subject was a cannabis user; this level represents the level of cannabinoids
present in his urine before the experiment started.
that this subject, a cannabis user, started the experiment with a
level of 36 ng/ml.
When an unhydrolysed urine sample is chromatographed under
neutral conditions and the eluate analysed by HPLC, only one peak
is seen, which has a retention volume of 10 ml. This corresponds to
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THC-11-oic acid and to its ester glucuronide. When a sample is hy
drolysed under the conditions given above and analysed by HPLC
using an acidic eluent (pH 5.5) for HPLC, three cross-reacting can-
nabinoids are seen (figure 2).
FIGURE 2. HPLC-RIA chromatogram of a hydrolysed urine sample from an
individual suspected of having smoked cannabis.
The first peak (retention volume 13.5 ml) is the glucuronide ester
of THC-11-oic acid, the second peak (retention volume 16.6 ml) is
THC-11-oic acid, and the third peak (retention volume 30 ml) is the
methyl ester of THC-11-oic acid. The identities of all three peaks
have been established by GC-MS. The predominant THC metabolite
in urine, as detected by the antiserum used in this work, is there-
fore the glucuronide ester of THC-11-oic acid. Under the conditions
of hydrolysis used above, this glucuronide is transesterified to the
methyl ester of THC-11-oic acid, which is then hydrolysed to the
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free acid. The three peaks may be used as confirmation of the pres-
ence of cannabinoids in the urine sample in the same way as de-
rivatives are used for proof of identity in GC analyses. In some
cases a quicker analysis for urine may be required, in which case
the hydrolysis conditions may be made more vigorous (100°C for 15
min using an equal quantity of 1M sodium hydroxide in methanol)
when the glucuronide peak is completely hydrolysed or transesteri-
fied and the methyl ester is completely hydrolysed to yield a single
peak in the HPLC-RIA chromatogram for THC-11-oic acid (16).
Because the antiserum used in this study is very selective for
cannabinoids, the RIA may be used to detect cannabis misuse in fo-
rensic cases by screening serum, plasma, haemolysed blood or
urine for the presence of cannabinoids. Those which are negative
may be reported as such, whilst those which are positive may be
analysed by the HPLC-RIA procedure. Not only will this give addi-
tional proof of the presence of cannabinoids, but it will enable each
cannabinoid to be identified and quantified. Three years’ experi-
ence using this method has shown that levels of THC in blood sam-
ples submitted for forensic analyses are usually very low, whilst
levels of the glucuronide ester of THC-11-oic acid are much higher.
This is an added reason for the use of a relatively nonselective
antiserum to detect all the cannabinoids whilst using the HPLC
procedure to separate them. The application of this method to the
analysis of cannabinoids in fatally injured drivers has been report-
ed (17), as has its use for the analysis of samples submitted for fo-
rensic examination (18).
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An EMIT Assay for Cannabinoid
Metabolites in Urine
M. J. DeLaurentis, K. McNeil, A. J. Mann, S. Clark,
and Helena M. Greenwood
INTRODUCTION
An assay to detect cannabinoid metabolites in urine has been de-
veloped for application as a screening test for the use of marijuana.
The technique employed was homogeneous enzyme immunoassay
(EMIT), a non-isotopic immunoassay method first described for the
measurement of morphine in urine (1). The immunoassay employs
an enzyme as label. When the antigen to be assayed is conjugated
to an enzyme, the enzyme activity may be modified by antibody
binding. This forms the basis of the assay, where enzyme activity is
directly proportional to the free antigen concentration. Four en-
zymes have been employed in the development of assays for drugs,
both in urine and serum, for endogenous haptens and more recent-
ly for serum proteins; these applications of the technique have
been reviewed elsewhere (2,3).
Further application of the technique, using MDH conjugated
with a derivative of tetrahydrocannabinol ( THC), has demon-
strated that the procedure is equally useful in the determination of
cannabinoids in urine. Pig heart mitochondrial malate dehydrogen-
ase (MDH) E.C. 1.1.1.37 was chosen for development of a THC assay
because of its availability and its ease of detection. This, together
with antibodies raised in sheep, enabled development of a rapid,
sensitive and specific assay where as little as 20 ng of THC togeth-
er with its metabolites can be detected in a 1-minute spectrophoto-
metric measurement.
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ASSAY DEVELOPMENT
In order to develop an assay which would detect most commonly
occurring cannabinoid metabolites present in urine, antibodies
were raised against a molecule derivatized at a point common to
many such metabolites. The principal metabolites believed to be
present in urine are shown in figure 1. The desired acid (I) was
FIGURE 1. Structures of THC and metabolites believed to be present in urine.
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produced by the method previously described (4) and was conjugat-
ed to the enzyme, pig heart malate dehydrogenase. The mechanism
of inhibition of hapten conjugates of MDH has been previously de-
scribed in an immunoassay for morphine (5). Antibodies to the can-
nabinoid metabolites were obtained from sheep by immunization
with a bovine gamma-globulin conjugate of the acid (I).
When the THC acid derivative was conjugated to MDH and
mixed with an antibody excess, a 60% inhibition of enzyme activity
resulted. This inhibition could be reversed by addition of increasing
amounts of THC acid such that it was possible to develop an
assay in which drug concentration is directly proportional to activi-
ty of the MDH conjugate. Using a spectrophotometer, the enzyme
rate is followed at 340 nm by measuring the rate of conversion of
the coenzyme NAD into NADH.
Assay Protocol
Using the Syva Model 1500 Pipetter/Diluter, 50 µl of urine
sample is delivered to a sample cup with 250 µl of buffer which
contains the enzyme substrate, malic acid. By sequentially adding
1) 50 µl of antibody reagent, which contains antibodies to a THC
derivative and coenzyme nicotinamide adenine dinucleotide (NAD),
together with 250 µl of buffer and 2) 50 µl of enzyme reagent plus
250 µl of assay buffer, the final reaction mixture is produced. The
mixture is aspirated into the flowcell of a spectrophotometer,
where the enzyme rate is measured at 30°C for 30 seconds follow-
ing a 15-second delay. Enzyme activity is proportionally reduced
when the labeled drug combines with antibody; the active enzyme
converts NAD to NADH, resulting in an absorbance change that is
measured spectrophotometrically at 340 nm.
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Calibration
Three EMIT calibrators are employed in the assay; the Negative
calibrator contains no drug (0.0 ng/ml) and the Low (20 ng/ml) and
Medium (75 ng/ml) calibrators contain the drug derivative, 11-nor-
THCScarboxylic acid. Since -THC acid is difficult both to iso-
late and to prepare, -THC was selected to act as calibrator for
the assay. -THC acid is more readily available than the -THC
acid, and it exhibits virtually identical immunochemical reactivity
in this system.
For a positive/negative interpretation, the Negative (0.0 ng/ml)
and Low (20 ng/ml) calibrators are used. The difference between
the rate observed for the Negative calibrator and the rate observed
for the Low calibrator is used as a reference which permits differ-
entiation of urine samples containing no detectable drug from
those containing drug. The Low calibrator (cut-off) contains a pre-
determined quantity of drug derivative which ensures that at least
96% of all samples that contain levels of cannabinoids equal to or
in excess of the detection limit of the assay (50 ng/ml) yield a posi-
tive response, and at least 96% of samples containing no cannabin-
oids give a response less than that of the calibrator.
To test for the presence or absence of cannabinoids in urine, it
was necessary to select this specific minimum reading (cut-off)
above which samples can be identified as positive. For the EMIT
Cannabinoid Assay, the response of the Low calibrator (nominal
concentration 20 ng/ml) serves as the cut-off, since it was found to
give a rate which discriminates effectively between samples con-
taining 60 ng/ml and samples containing no drug. This was con-
firmed by assaying 60 samples known to be negative for THC, both
before and after spiking each of them with 60 ng/ml THC acid.
The results, when plotted as a histogram, show the separation be
tween the two populations with no overlap between positive and
negative samples (figure 2).
Alternatively, a standard curve (figure 3) for the assay can be
prepared by plotting the assay reading ( of the Negative, Low,
and Medium calibrators against the concentration on semi-log
graph paper. A semiquantitative result can then be estimated from
the standard curve. Because of sample-to-sample variation and the
fact that the assay detects certain cannabinoid metabolites and an-
alogs with different sensitivity from that of the calibrator drug, se-
miquantitative results for positive samples can only be estimated
in analyte equivalents.
FIGURE 2. Histogram showing assay response of 50 THC negative samples and the
same samples spiked with 50 ng/ml 11-nor- carboxylic acid.
FIGURE 3. Response curve for the EMIT Cannabinoid Assay.
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Specificity/Cross-Reactivity
The cross-reactivity of the EMIT Cannabinoid Assay to a wide
range of cannabinoid compounds, particularly those thought to
occur in urine, was studied by adding each compound to a THC-
negative urine pool. Employing a representative lot of reagents, the
urine samples were assayed using the protocol described. Cross-re-
activity was defined as the concentration necessary to produce a re-
sponse in the assay equivalent to the cut-off, 20 ng/ml THC acid.
The compounds that were tested are shown in figure 4.
Cross-reactivity of the common urinary metabolites in the assay
was found to be high. In comparison the cross-reactivity to the
parent drug, THC, which is not found in urine, was slightly less.
Cross-reactivity between the THC acid and THC acid used to
calibrate the assay was determined to be approximately 100%.
To examine the cross-reactivity of the assay to various hormones,
drugs and their metabolites, each compound in table 1 was studied
by the same method. None of the non-cannabinoid compounds
tested exhibited clinically significant cross-reactivity.
TABLE 1. Non-Cannabinoid Compounds Tested That Produce a
Response Less Than That of the Cutoff Calibrator
(< 20 ng/ml 11-nor- -THC-9-carboxylic acid)
Acetylsalicyiic acid
Amitrlptyline
Amphetamine
Benzoyl ecgonine
Carbamazepine
Chlordiazepoxide
Codeine
Cortisol
Demerol
Dextromethorphan
Diazepam
Diphenyihydantoin
Ephedrine
Giutethimide
lmlpramlne
Medazapan
Methadone
Methaqualone
Methyiphenidate
Naioxone
PEMA
Phencyclidine
Phenobarbital
Phenyipropanolamine
Primidone
Promethazine
Propoxyphene
Propranolol
Quinidine
Secobarbitai
Theophylline
Thorazine
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FIGURE 4. Cross-reactivity of a representative reagent lot to various cannabinoid
compounds.
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CLINICAL STUDIES
Smoking Study
In a controlled study using the EMIT Cannabinoid Assay, three
male and three female subjects, all regular users of marijuana, ab-
stained from smoking for at least 6 days (10 days maximum). Each
subject then smoked two marijuana cigarettes, each containing 9
mg THC, within a 2-hour interval. Urinary cannabinoid levels were
monitored over the following 10-day period (figures 5 and 6) during
which the subjects abstained from further marijuana use.
As can be seen from figures 5 and 6, the data from the controlled
study indicate that urinary cannabinoid levels of regular users of
marijuana, male and female, may be in excess of 20 ng/ml for 4 to
10 days and longer after smoking. Although the cannabinoid levels
detected with the EMIT Cannabinoid Assay were highest at the be-
ginning of the study, it is not possible to distinguish between recent
use (within 24 hours) and infrequent use (up to 10 days).
Specificity Study
To evaluate the assay for potential cross-reaction due to non-
THC drug metabolites, clinical investigators were asked to assay as
many samples as possible that were known to contain drugs or
drug metabolites other than THC (figure 7). The presence or ab-
sence of cannabinoids in these samples was not confirmed by a
non-immunochemical technique.
As can be seen from the figure, there appears to be no correla-
tion between samples positive for cannabinoids and samples posi-
tive for other drugs, implying that no crossreactivity exists be-
tween these compounds. In the case of alcohol, sulfasalazine, and
meprobamate, only samples positive for both THC and drug were
observed. The number of samples was small, however, and no con-
clusion regarding potential cross-reactivity with these compounds
and/or their metabolites should be made. No confirmation of the
presence or absence of THC metabolites was performed on these
samples.
Compounds appearing to cause no interference with the EMIT
Cannabinoid Assay include methadone, cocaine, morphine, PCP,
barbiturates, amphetamines, opiates, and benzodiazepines.
FIGURE 5. Cannabinoid smoking study (Male Subjects); data points represent
response produced by urine samples when assayed by the EMIT Cannabinoid Assay.
FIGURE 6. Cannabinoid smoking study (Female Subjects); data points represent
response produced by urine samples when assayed by the EMIT Cannabinoid Assay.
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Sample Population Screening
Accuracy proved difficult to assess due to the lack of an estab-
lished and available reference method. Confirmation in this evalua-
tion was available only through confirmed recent use and experi-
mental smoking studies.
Table 2 summarizes the data generated in population screens
conducted as part of the clinical investigations performed using the
EMIT THC Assay. At the methadone maintenance clinic (III), over
75% of the individuals whose urine produced positive results (>50
ng/ml) admitted to smoking marijuana during the previous 3-6
days, and at prisons and parole centers (IV), 100% of the individ-
uals with positive samples admitted to recent use.
TABLE 2. Incidence of Samples Assaying Positive for THC by
EMIT ASSAY
Number
Samples
Run
Number %
Positive Positives
I. Smoking Study 28 7* -
II. Drug Treatment Program 95 64 87
III. Methadone Maintenance Clinic 211 115 55
IV. Prison/Parole Centers 246 125* 51
V. Toxicology/Forensic Laboratory 78 36 49
VI. Methadone Treatment Clinic 48 12 25
VII. Forensic/Criminal Laboratory 184 112 61
VIII. Hospital Emergency Room Patients 96 24 25
*100% Admission to Recent Use
Within the various populations studied, the incidence of samples
positive for cannabinoids ranged from 25% to 67%. The cumulative
results for all populations screened identified 491 positive speci-
mens from a total of 958 samples, an overall positive incidence of
51%. During the study, it was reported that the investigators gen-
erally found the frequency of positive results to be realistic for the
populations studied.
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DISCUSSION
A rapid, simple assay for the detection of urinary cannabinoid
metabolites has been developed for use as a screening test. Further
studies are underway to establish the duration of time after smok-
ing that one may detect cannabinoids in urine by this method and
the effects of intersubject variability in the rate of metabolism of
the drug. As the assay has been designed as a screening test, any
results should be confirmed by a nonimmunological technique. It
should be noted, however, that the reference method, gas chroma-
tography-mass spectrometry, may not employ a hydrolysis step in
the sample extraction, and therefore may only detect the unconju-
gated forms of the urinary metabolites. The degree of cross-reactiv-
ity of the EMIT assay to the conjugated metabolites is currently
being investigated. These metabolites may constitute a large pro-
portion of the cannabinoids in urine and the degree of conjugation
may vary from subject to subject.
It is felt that the availability of a rapid, simple screening test for
cannabinoids will greatly facilitate studies regarding the medical,
demographic, and social use of marijuana.
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Laboratory Evaluation of
Immunoassay Kits for the Detection
of Cannabinoids in Biological Fluids
Michael A. Peat, Bryan S. Finkle, and Mary E.
Deyman
The Center for Human Toxicology has, together with other
toxicology laboratories, been involved in the field evalua-
tion of a radioimmunoassay procedure for the detection and
quantitation of THC in serum and an enzyme multiplied
immunoassay procedure for the detection of the nor-carbox-
ylic acid metabolite in urine. Each laboratory was selected
on the basis of proven experience with commercially availa-
ble immunoassay procedures. Initially, the study was de-
signed to screen samples collected from accident casualties;
however, at some of the study sites the data base was ex-
tended to include other samples.
The radioimmunoassay procedure evaluated was developed
at the Receptor Research Institute, and involves the use of
a tritium-labeled -THC tracer. A total of eight laborato-
ries participated in the evaluation of this method, which is
prepared in kit form by the manufacturer. Thirteen labora-
tories evaluated the EMIT procedure developed at Syva
Corporation.
The study protocol required that each site screen serum and
urine samples and forward all presumptive positive speci-
mens to the Center for Human Toxicology. These positive
specimens were then shipped to either Battelle Laboratories
or Research Triangle Institute for confirmation analysis by
gas chromatography-mass spectrometry.
The results of these evaluations will be presented and will
include:
1. Correlations of positive RIA and EMIT analysis with
gas chromatography-mass spectrometry results;
2. The results of quality-control tests;
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3. Criticisms and suggestions made by analysts at each site;
4. The results of evaluations performed at the Center for
Human Toxicology.
INTRODUCTION
The widespread use of marijuana among the population of the
United States has led to the need for intensive research into the
pharmacological and psychological effects of tetra-hydrocanna-
binol ( THC), the principal active ingredient in marijuana. Fur-
thermore, THC is now being studied for possible therapeutic use.
Together with the need to analyze plasma samples from these basic
research programs there is an increasing demand from forensic
and clinical toxicologists for improved analytical procedures to
screen and quantitate THC and its metabolites in biological
fluids.
One analytical technique which appears to be particularly favor-
able because of its sensitivity and specificity is radioimmunoassay
(RIA). In fact, several groups (1,2,3,4,5) have developed such proce-
dures. Those developed by Cook et al. (1,2) and Gross et al. (3) are
reported to be specific for THC. The procedure developed by
Gross et al. at the Receptor Research Institute (RRI) was evaluated
under service laboratory conditions.
A variety of other immunoassay techniques are in common use,
including the homogeneous enzyme immunoassay (EMIT) proce-
dure. This analytical method has been applied to urine samples for
the analysis of several drugs of abuse and to the quantitation of a
variety of drugs and metabolites in serum. Rodgers et al. (6) devel-
oped a semiquantitative EMIT assay for cannabinoid metabolites in
urine and this procedure has since been further refined. It was also
evaluated during the course of the project.
The RIA kit from RRI was designed specifically for the assay of
serum samples. It is a direct procedure involving no prior extrac-
tion or chromatography and uses a tritium-labeled THC tracer.
The method uses 10 µl of serum which is incubated with 100 µl of
THC antibody and 500 µl of the [3H] THC tracer. Separation
of the unbound THC is by dextrancoated charcoal, and the tech-
nique is reported to be sensitive to 5 ng/ml.
The EMIT assay was designed specifically for the detection of
urinary metabolites structurally similar to 11-nor- THC-9-carbox-
ylic acid (THC-9-acid). 11-Nor THC-9-carboxylic acid is used to
calibrate the assay. 50 µl of urine are mixed with THC antibody
reagent (malate dehydrogenase covalently linked to THC) and nico-
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tinamide adenine dinucleotide, a substrate for the enzyme. The en-
zymatic reaction rate is measured spectrophotometrically at 340
nm for a 30-second time period at 30°C. The procedure can detect
50 ng/ml of THC-9-acid in urine with greater than 95% confidence.
This project was designed to evaluate both the RIA and EMIT
procedures under service laboratory conditions. Each laboratory in
the project was primarily an analytical toxicology laboratory in-
volved in forensic and/or clinical toxicology. The study was de-
signed initially to screen samples collected from accident casualties
and, therefore, each laboratory was requested to assure the confi-
dentiality of the victim before inclusion in the study. During the
course of the study it became increasingly apparent that the antici-
pated sample population would not be obtained. This was particu-
larly so with the RIA procedure, mainly because of the number of
hemolyzed blood samples encountered. In order to increase the
sample population, a few laboratories were asked to use the analy-
sis kits on other types of specimens; for example, routine drug-sus-
pected emergency room admissions.
The study protocol required that each site screen serum and
urine samples and forward all presumptive positive specimens to
the Center. They were then shipped to either Battelle Laboratories
or Research Triangle Institute for quantitative analysis by gas
chromatography-mass spectrometry (GC-MS).
SELECTION OF SITES
Each laboratory in the study was selected on the basis of proven
experience with commercially available immunoassay procedures.
This was achieved by personal communication and by evaluation of
responses to a questionnaire.
Twenty laboratories were asked originally to participate in the
study. In addition, during the course of the study four further sites
asked to be included and a number of sites withdrew. Seven labora-
tories evaluated the RIA kits and twelve the EMIT procedure. In
addition to these sites, the laboratory at the Center for Human
Toxicology was involved in the evaluation of both procedures.
RECEIPT AND SHIPMENT OF KITS
Evaluation of the RIA procedure began in December 1978 and
continued until August 1979. Two hundred kits were received at
CHT from RRI, of which 98 were used in the study. The dates of
receipt and kit expiration are shown in table 1.
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TABLE 1. Date of Receipt and Expiration of RIA kits
Number of
Kits Received Lot Number
Date of
Receipt
Date of
Expiration
10 X4A 10-10-78 1-15-79
40 X4A 11-29-78 1-15-79
50 X5A 12-20-78 2-15-79
50 X6A 4-04-79 5-15-79
50 X7A 6-26-79 8-15-79
Some laboratories, including CHT, encountered abnormally high
nonspecific binding with the kits (Lot no. X6A) received on 4-4-79.
Replacement antibody was forwarded to CHT on 6-26-79. All of
these kits were shipped to CHT from RRI by overnight air courier
service and were received in a satisfactory condition.
A total of 120 EMIT kits were received during the period May
through August 1979. Although these kits were not in their final
marketing form, i.e., the enzyme preparation was not lyophylized,
inhouse evaluation indicated that they were satisfactory. Towards
the end of the study period a small number of lyophylized kits
were received and forwarded to some sites. Unfortunately, this was
too late for evaluation of these particular kits to be completed.
Approximately 60 EMIT kits were shipped by overnight service
to the sites or used at CHT. It is impossible to give a more accurate
estimate because towards the end of the project,, calibrator solu-
tions and buffer solutions were shipped separately.
COLLECTION OF SAMPLES
The exact protocol for collection of samples at each site was the
responsibility of the investigator at the particular site. It was
stressed to those sites evaluating the RIA procedure that the kit
was designed for the assay of plasma/serum samples and not for
hemolyzed blood specimens. A number of sites, however, did in fact
use the kit to screen hemolyzed blood. After collection of serum/
plasma samples it was recommended that they be stored frozen in
glass tubes and, if possible, protected from light. Similar recom-
mendations were made for storage of urine samples.
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It was intended at first to limit the sample population to serum/
plasma or urine collected from accident victims; however, analyt-
ical problems with hemolyzed blood samples and the late arrival of
the EMIT kits made it clear that the anticipated sample population
would not be met. To increase the number of specimens analyzed,
it was decided to allow certain sites, including CHT, to screen other
samples using the test kits. Although this increased the number of
samples, the total number analyzed by RIA over a period of 12
months was still below that anticipated originally. A more statisti-
cally useful number of samples were screened in 6 months, using
the EMIT procedure.
TASKS OF THE PARTICIPATING LABORATORIES
Each participant was responsible for:
1. Collection of samples
2. Analysis of samples by immunoassay
3. Shipment of presumptive positive samples to CHT by
overnight air courier service
Participants were also asked to complete a questionnaire de-
signed to obtain information about the accident and possible drug
involvement, and to record the analytical results. The completed
questionnaires were returned to CHT together with the presump
tive positive samples.
Although these tasks appear to be relatively simple, it is impor-
tant to realize that each of the participants was responsible for a
forensic or clinical toxicology laboratory with a heavy routine
workload. In the case of the RIA procedure, the entire assay could
employ a skilled technician for as much as 2 days at a time, and
this also contributed to the small number of samples screened by
this technique.
CONFIRMATION OF PRESUMPTIVE POSITIVES BY GAS
CHROMATOGRAPHY-MASS SPECTROMETRY
All the presumptive positives were shipped from each site to
CHT by overnight air courier service They were then sent to either
Dr. R.. L. Foltz, of Battelle Laboratories, or Dr. J. Bursey, of Re-
search Triangle Institute, for GC-MS confirmation. Dr. Foltz was
responsible for analyzing approximately half of the plasma samples
and Dr. Bursey for the remainder of these samples and all of the
urine samples.
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The analytical method used to assay the plasma samples was de-
signed to detect -THC specifically, and that used for the urine
samples to detect the 11-nor- -carboxylic acid metabolite. A small
number of urine specimens were hydrolyzed before extraction.
QUALITY CONTROL SAMPLES
At regular intervals throughout the study, serum samples
“spiked” with THC were supplied on a blind basis to each site
evaluating the RIA procedure. These were prepared according to
the following protocol: A 203 mg/ml THC solution supplied by
NIDA was serially diluted to a 20.3 (A) and 2.03 ng/µl (B) concen-
tration with ethanol. These solutions were then used to “spike”
serum; for example, 50 µl of B in 25 mls of serum resulted in a
THC concentration of 4.06 ng/ml. Each batch of samples was
shipped in dry ice by overnight air courier service to each labora-
tory.
RESULTS
RIA
The participants evaluating the RIA procedure analyzed a total
of 310 samples of which 43 (14 percent) were identified as presump
tive positives. Approximately one-third of this latter group were he-
molyzed. The results of quantitation of samples analyzed by both
RIA and GC-MS are shown in table 2. The number of hemolyzed
samples included in this group is unknown.
Quality control specimens, prepared in serum, were sent to each
site participating in the RIA evaluation. Table 3 shows the results
of these analyses. Some of the regression coefficients were as fol-
lows:
GC-MS against RIA:
“Spiked concentration”
against:
Total minus sample 4
GC-MS (samples 1-22*)
CHT (samples 1-22*)
RRI (samples 1-12*)
*Excluding sample 4
(n=97) r=0.777
(n = 21) r = 0.959
(n = 29) r = 0.802
(n = 19) r = 0.950
In addition to analyzing the quality control specimens, a number
of plasma samples from the Emergency Room of the University of
Utah Medical Center were also analyzed at CHT; these were paired
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TABLE 2. Results of RIA and GC-CIMS Analysis
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RIA
(ng/ml)
GC-MS
(ng/ml)Site Site
RIA GC-MS
(ng/ml)
I 6.6 0
5.0 Not Analyzed
6.4 0
6.5 Less than 1
15 9.3
9.0 9.9
23 Interference
6.5 6.5
9.4 0
6.5 6.2
15 5.0
II 7.0 2.0
III 15 10.5
9.0 3.0
4.0 0
IV Positive 86
Positive 31
Positive 220
Positlve 155
Positive 72
Positive 69
Positive 11
Positive 3.0
Positive 21
Positive 0
Positive 10
Positive 0
Positive 5.2
Positive 4.6
Positive 3.1
Positive Interference
with urine samples collected from the same patient and screened
positive by EMIT. Table 4 shows the data obtained by RIA and GC-
MS.
EMIT
A total of 13 laboratories, including CHT, were involved in the
evaluation of this procedure during the period June to December
1979. The 12 sites screened a total of 596 samples from accident vic-
tims, of which 165 (28%) were identified as presumptive positives.
Some of these sites used the EMIT procedure to screen for posi-
tives and negatives only, whereas others determined the concentra-
tion of metabolites present. It must be remembered that initially
the GC-MS procedure quantitated only the free 11-nor-carboxylic
acid metabolite, and Williams and Moffatt (7), reported that up to
80% of the acid metabolites are conjugated in the urine. From
these initial data, 18 of the samples were screened positive by
EMIT but were negative for the carboxylic acid metabolite by GC-
MS. Subsequently several samples with low or negative GC-MS re-
sults were hydrolyzed enzymatically and then reanalyzed by GC-
MS for the 11-nor-9-carboxylic acid metabolite. Table 5 shows the
results of these analyses.
TABLE 3. Results of Quality-Control Specimens (All Concentrations ng/ml)
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TABLE 4. Plasma Samples from Subjects Whose Urine was
Screened Positive by EMIT
Sample RIA GC/MS Sample RIA GC-MS
No. (ng/ml) (ng/ml) No. (ng/ml) (ng/ml)
1 7 0 6 0 1.3
2 0 0 7 0 0
3 <5 0 8 10 <1
4 <5 0 9 0 2.1
5 11 0 10 0 0
TABLE 5. Results of EMIT and GC-MS Analyses After
Enzymatic Hydrolysis
EMIT GC-MS of Free Acid GC-MS After Hydrolysis
(ng/ml) (ng/ml) (ng/ml)
Positive 4.6 42
Positive 0 4
Greater than 75 36 600
53 7.1 32
0 0 4
Greater than 75 31 75
10 6.5 7.9
11 0 2.7
75 6.2 58
0 24 Less than 2
0 0 47
Greater than 75 5 31
Greater than 75 2.1 53
Greater than 75 0 43
Greater than 75 2.1 77
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CHT was closely involved in the evaluation of the EMIT proce-
dure and examined a large number of samples. Of these, 106 were
analyzed by both EMIT and GC-MS. The results are tabulated in
table 6. A total of 37 samples screened positive by EMIT but were
unconfirmed by GC-MS for the free acid metabolite. Subsequently 3
of these were hydrolyzed enzymatically and found to be positive by
TABLE 6. Results of EMIT Analysis at CHT and GC-MS Analysis
for the Free Acid Metabolite at RTI
EMIT GC-MS EMIT GC-MS EMIT GC-MS
(ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml)
12 0
30 4.0
Greater than 75 21
14 8.1
Greater than 75 55
Greater than 75 9.1
34 26
37 35
15 0
21 0
0 0
18 17
0 0
55 24
15 4.4
20 20
16 0
11 2.2
0 0
62 29
0 0
66 38
15 5
0 20
0 0
14 26
12 0
14 14
0 0
Greater than 75 5
30 0
21 3.5
57 2.9
52 3.6
37 0
52 42
0 0 57 20
0 0 Greater than 75 50
12 11 15 7.5
Greater than 75 36 58 22
0 0 36 2.6
53 7.1 60 30
23 0 Greater than 75 26
Greater than 75 31 27 3.3
10 6.5 Greater than 75 41
11 0 Greater than 75 7
0 0 60 9
Greater than 75 6.2 Greater than 75 45
0 24 Greater than 75 11
0 2.3 Greater than 75 5
19 0 Greater than 75 2.1
10 17 54 0
35 0 Greater than 75 2.1
15 4 33 145
0 29 10 4
0 20 24 0
Greater than 75 10 Greater than 75 2.1
10 4 22 2.5
74 22 66 78
24 25 Greater than 75 37
50 2.5 Greater than 75 39
0 10.5 56 70
Greater than 75 3.4 37 18
0 0 Greater than 75 67
0 7.8 33 2.5
0 7 Greater than 75 27
13 5 25 26
72 32 Greater than 75 0
35 4 34 0
25 0 40 2.6
23 0 18 0
EVALUATION OF IMMUNOASSAY KITS 95
GC-MS. More importantly, perhaps, 8 samples from the CHT data
screened negative by EMIT but positive by GGMS, although 4 of
these had free carboxylic acid metabolite concentrations of less
than 15 ng/ml (i.e. less than the low calibrator for EMIT) by GC-
MS. It should be noted that the 12 participants did not forward any
“negatives” for GC-MS confirmation, so the true number of “false
negatives” may have been higher.
Plasma and urine samples from some patients were analyzed by
EMIT, RIA and GC-MS methods. Of those plasma samples in which
no THC was detectable by GC-MS, 12 of the corresponding
urines were positive by both EMIT and GC-MS, 5 plasmas positive
by GC-MS, 11 of the corresponding urines were positive by both
EMIT and GC-MS, whereas 3 were positive by EMIT only, although
in these cases the urines were not hydrolyzed.
DISCUSSION
Certainly the most disappointing aspect of the entire study was
the lack of response to the RIA evaluation. The time-consuming
procedure and problems with the kit itself were the most common
explanations given by the participants. In addition, the kit was de-
signed to assay serum samples, whereas the real need among those
laboratories chosen for the study was for a kit to screen hemolyzed
blood samples and, in fact, the kit was inappropriately used at
some laboratories to do this.
The correlation between GC-MS and RIA on the case samples
analyzed by the participants was far from adequate. At the 6 sites
reporting data, six false positives (1.9% of the total, 13.9% of the
presumptive positives) were found, although it is possible that some
of these were hemolyzed. Of 10 plasma samples analyzed at CHT
from subjects with positive urines (by EMIT), 2 showed values by
RIA above the sensitivity limit of the assay which were subsequent-
ly shown to be zero by GC-MS.
Six of the laboratories and CHT were involved in the analysis of
the quality control samples. The data from these samples is shown
in table 3. It is interesting to note that the performance at CHT
improved throughout the study as the laboratory staff became
more familiar with the procedure. It is also worthwhile to note that
those sites with personnel experienced in RIA techniques per-
formed better than those new to the use of tritiated tracers.
The regression coefficients (GC-MS vs. RIA) for participating
sites are greater than 0.93 for all but two sites. One of these
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achieved only 0.46, but this is much improved if one obvious error
is eliminated. Since the kit is prepared in a form suitable for mar-
keting, consideration must be given to the fact that laboratory ex-
perience with this type of kit is essential for adequate results.
At the end of the study a questionnaire was forwarded to each
site. One of the questions asked was at what lower concentration
limit the kit was unreliable when applied to serum. There was, of
course, variation in the responses, one laboratory suggesting 2 ng/
ml, three auggesting 6 ng/ml and two 10 ng/ml. Our own experi-
ence at CHT suggests a limit between 5 and 10 ng/ml when the
procedure is used by inexperienced personnel. Whether this is ade-
quate for forensic case work is questionable in view of recent data
on the blood concentrations of THC to be expected in medico-
legal cases (Williams and Moffatt, 1980). The kit instructions indi-
cate an expected sensitivity of 5 ng/ml when applied to serum.
Each participant was also asked to describe briefly his or her
views concerning the kit and the instructions and to comment on
the usefulness of the procedure. Generally, all the participants
found the kit and instructions to be satisfactory. Most, however, re-
ported that they had trouble with the standards at the lower end of
the curve (5 to 10 ng/ml), particularly with reproducibility from
assay to assay, and they suggested that samples falling in this
range be repeated. One participant reported:
“Overall, I feel that the kit should be developed and laced
into laboratory use, especially in cases involving traffic ac-
cidents, drunken driving, bizarre accidents and coroner’s
cases in general.”
This view was echoed by the other participants.
A total of 12 laboratories and CHT evaluated the EMIT proce-
dure. Because the technique was simple and familiar, all sites
found the kit easy to use. The kit was compared to a GC-MS assay
developed by Dr. Joan Bursey, of Research Triangle Institute. The
assay was designed to quantitate the 11-nor- THCScarboxylic
acid metabolite, whereas the kit was designed to detect “cannabin-
oid metabolites” which resembled this acid metabolite in structure.
This fact alone could explain the poor correlation between the
EMIT values and those obtained by GC-MS, particularly those sam-
ples with considerably higher EMIT values. However, if the data in
table 4 are considered, it is much more likely that the discrepancy
is due to the EMIT responding to the glucuronide conjugate of this
metabolite. Unfortunately, in most cases the sample volume was
insufficient for reanalysis of the urine by GC-MS after hydrolysis.
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It is much more difficult, however, to account for those samples
with a significantly lower EMIT value:
EMIT (ng/ml) GC-MS (ng/ml)
0 20
14 26
0 29
0 20
0 10.5
0 7.8
0 7
33 145
As with the RIA procedure, a questionnaire was sent to each par-
ticipant, requesting views and comments. Generally, the partici-
pants had few problems. Some questions were raised concerning
the procedure for running blanks and whether the kit was satisfac-
tory for postmortem urine because of the extreme turbidity some-
times seen in such samples. The introduction of the lyophilized rea-
gents has been reported to alleviate these problems.
The interpretation of EMIT urine analyses from both a medico-
legal and clinical viewpoint should be approached with caution. Of
34 cases in which both plasma and urine were analyzed, both sam-
ples were positive in only 14 cases, showing that a positive EMIT
reading does not necessarily correlate with the recent smoking of
marijuana, if the presence of THC in plasma is taken to indicate
recent use. In addition, a practical difficulty is that the confirma-
tion of the urine EMIT readings is not a straightforward process
because current GC-MS procedures are designed to quantitate only
the free 11-nor- -THC-9-carboxylic acid metabolite. Hydrolysis of
the conjugated metabolites becomes important if such techniques
are to be used.
CONCLUSIONS
There is a demand for analytical screening procedures for
THC in serum and/or blood and for cannabinoid metabolites in
urine. Development of the EMIT procedure has come a long way
towards satisfying the latter demand, although some effort should
be directed towards developing a more complete confirmatory pro-
cedure.
The analysis of THC in serum and/or blood is more complex.
In this case the GC-MS confirmatory method is acceptable, al-
though further refinements are needed so that it will be applicable
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to all types of blood samples and so metabolites can be clearly sepa-
rated and identified.
Screening serum and blood samples using a tritiated RIA kit is
still a very difficult and time-consuming procedure. The kit should
not be used by inexperienced personnel for quantitation of THC.
To help overcome some of the problems encountered with the
RIA procedure evaluated, we would recommend the development of
an iodinated I125) tracer for THC and also for either the 11-hy-
droxy or carboxylic acid metabolite. In our opinion, the latter
would improve both the quantitation and the confidence of the
screening assay.
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Quantitative Analysis for THC,
11-Hydroxy- -THC, and 9-Carboxy-
 THC in Plasma Using GC/CI-MS
Rodger L. Foltz and Bruce J. Hidy
A method for quantitative measurement of   THC concen-
trations in plasma has been developed and applied to the
analysis of more than 2000 samples over the
The method includes addition of deuterium-labeled THC
to the plasma for use as the internal standard, a simple
and relatively rapid solvent extraction procedure, formation
of the trimethylsilyl derivative, and quantitation by select-
ed ion monitoring using ammonia chemical ionization. A
similar procedure has also been developed for simultaneous
analysis of THC and two of its major metabolites in
plasma. The latter procedure requires use of a glass capil-
lary column for assays of plasma samples in which the
THC concentration is below 10 ng/ml. Sensitivities for both
methods permit quantitation of THC and its metabolites at
concentrations as low as 0.2 ng in 1-ml plasma samples.
INTRODUCTION
Interest in the pharmacology of cannabinoids continues at a high
level, owing to the widespread use of marijuana and the discovery
of potentially beneficial medical applications for te t ra -
hydrocannabinol. Cannabinoid research has been hampered by
the limited availability of analytical facilities capable of measuring
the typically low levels of cannabinoids in physiological fluids after
cannabinoid administration. For the past 4 years Battelle Colum-
bus Laboratories has provided an analytical service to NIDA-au-
thorized scientists engaged in cannabinoid research. The cannabin-
oid assays developed and used at Battelle are based on the combi-
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nation of gas chromatography and chemical ionization mass spec-
trometry (GC/CI-MS).
QUANTITATION OF THC
Measurement of THC in plasma by a GC/MS method was first
reported by Agurell et al. (1). Their procedure includes addition. of
a deuterium-labeled THC analog to the plasma, extraction, and
liquid chromatographic purification on a Sephadex LH-20 column,
followed by quantitative measurement using gas chromatography
and electron impact mass spectrometry (GC/EI-MS). The method
used at Battelle is similar except that it uses a relatively simple
extraction based on the procedure (figure 1) developed at the Re-
search Triangle Institute (2), and employs ammonia chemical ion-
ization rather than electron impact ionization (3). Using this proce-
dure, a set of 36 plasma samples can be extracted and prepared for
analysis by one technician in a period of 8 hours. An additional 8
hours is required to perform the GC/MS analyses.
FIGURE 1. Flow diagram for analysis of THC in plasma.
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Most of the THC analyses done at Battelle during the past 2
years have been performed on a Finnigan 4000 GC/MS coupled to
an Incos date system. With this system operating normally, as
little as 20 pg of derivatized THC injected into the GC/MS gives a
response sufficient to permit measurement with good precision.
Usually, only 10 to 20 percent of a derivatized extract is injected at
one time. Consequently, for a 1-ml plasma sample, concentrations
of THC as low as 0.2 ng/ml can be measured.
EXTRACTION PROCEDURE
All glassware should be thoroughly cleaned and silylated (4). The
THC standard solutions should be stored at  –10°C in the dark but
allowed to warm to room temperature just prior to use.
Transfer a measured quantity (normally 1 ml) of plasma to a 20-
ml culture tube equipped with a Teflon-lined screw cap. Add 100 µl
of an ethanol solution of the  THC-2H3 internal standard (200 ng/
ml) followed by 1.0 ml of a pH 7.0 buffer solution (Fisher Scientific
Co.). Vortex the mixture for 10 sec. Add 6 ml of high purity hexane
(Distilled-in-Glass, Burdick and Jackson Co.), tightly cap the tube,
and gently mix the contents for 20 min using an automated tube
rocker or rotator. Centrifuge for 6 min and then carefully transfer
the hexane (top) layer to a second culture tube using a disposable
Pasteur pipette. The remaining plasma residue can be discarded.
The hexane solution is now washed successively with dilute
alkali and dilute acid to remove strongly acidic and basic com-
pounds. Add 2.5 ml of 0.1 N NaOH solution to the hexane extract.
After capping the tube, rotate or rock for 20 min and then centri-
fuge. Using another disposable pipette, remove the aqueous
(bottom) layer and discard. Add 2.5 ml of 0.1 N HCl solution to the
hexane extract. Tap the tube gently to cause gas bubbles formed by
the acid-base reaction to escape. Again, tightly cap the tube, rock
or rotate it for 10 min, and centrifuge. Carefully transfer just the
hexane (top) layer to a 15-ml glass tube with a tapered or cone-
shaped bottom. Gently concentrate the extract to near dryness at a
temperature of 35-40°C using either a nitrogen stream or a rapid
evaporation device such as the Buchler Vortex-evaporator (Buchler
Instruments).
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The extract residue is now transferred to a l-ml glass vial having
a cone-shaped bottom and equipped with a Teflon-lined screw cap
in the following manner. Add 0.5 ml of high purity pentane to the
tube containing the residue and vortex the tube for 10 sec. Using a
disposable pipette, transfer the pentane solution to the 1-ml glass
vial. Repeat the last step using an additional 0.5 ml of pentane to
transfer any remaining extract residue to the 1-ml vial. Add 10 µl
of high purity dimethylformamide to the pentane solution to act as
a “keeper” to minimize evaporative loss of the THC during the
final evaporation and to serve as a solvent for the trimethylsila-
tion. Slowly concentrate the pentane solution by heating the glass
vial with a heating block maintained at 40°C. When all of the pen-
tane has evaporated (approximately 20 min), add 15 µl of bis-(tri-
methylsilyl) trifluoroacetamide containing 1 percent trimethylsilyl
chloride to the vial and cap tightly. Vortex the vial and then heat
in an oven at 90°C for at least 1 hour. The sample is now ready for
GC/MS analysis. However, the sample can be stored at –10°C in-
definitely.
GC/MS ANALYSIS
Chemical ionization with ammonia as the reagent gas is used for
quantitation of the trimethylsilylated THC because it affords
higher sensitivity and specificity than either electron impact ion-
ization or chemical ionization using methane or isobutane as rea-
gent gases (5). The method was developed on a quadrupole system,
but any mass spectrometer equipped for chemical ionization and se-
lected ion monitoring should be satisfactory, provided it has ade-
quate sensitivity. For systems in which the gas chromatograph is
connected directly to the mass spectrometer, methane (Ultrahigh
Purity grade, Matheson Gas Products, East Rutherford, NJ) should
be used as the carrier gas. If the GC/MS employs a separator,
helium may be used as the carrier gas. In both cases the ammonia
(Ultrahigh Purity grade, Air Products and Chemicals, Tamaqua,
PA) should be introduced into ion source via a makeup gas inlet so
that the ammonia and carrier gases enter the ion chamber in con-
centric gas streams. The ammonia flow rate into the ion source is
adjusted while observing ion intensities at m/z 18 and 35. As the
ammonia flow rate is increased, the intensity of the m/z 18 peak
(NH4
+) should at first increase and then reach a plateau, at which
point a peak at m/z 35 (NH3•NH4
+) appears and begins to increase
in intensity. The optimum ammonia flow rate is the point at which
the m/z 18 peak reaches a maximum and the m/z 35 peak just
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begins to increase in height. The total reagent gas pressure in the
ion chamber should be between 0.3 and 1.0 torr. If a separator is
used, it may be necessary to bleed in methane along with the am-
monia to achieve this total pressure.
Various gas chromatographic columns can be used, but the best
results have been achieved with a 1.8-m × 2-mm ID glass column
packed with 3 percent OV-17 on 100/120 mesh Gas Chrom Q (Ap-
plied Science Labs, State College, PA). The injector, column, and
transfer-line temperatures are maintained at 280°, 250°, and 320°C,
respectively. Under these conditions and a carrier gas flow rate of
approximately 15 ml/min, the THC-TMS should elute in ap
proximately 4 min. The resolution of the GC column can be evalu-
ated by injecting a solution containing an equal mixture of THC-
TMS and THC-TMS 50 µg/ml in hexane). Under the stated
GC conditions a good quality OV-17 column will give a chromato-
gram showing at least a detectable valley between the peaks corre-
sponding to the two cannabinoid derivatives.
For selected ion monitoring the mass spectrometer is set up to
monitor the ion currents at m/z 387 and 390, corresponding to the
protonated-molecule ions (MH+) for THC-TMS and THC-2H2-
TMS, respectively. After the CC/MS run is completed, the THC
plasma concentration is determined by measuring the areas of the
THC-TMS and THG2H2-TMS peaks in the selected ion cur-
rent profiles (“ion chromatograms”) and relating the peak areas
ratio to a previously established standard curve. A new standard
curve should be established whenever new standard solutions are
prepared or when analysis of plasma samples containing known
concentrations of THC shows unacceptable accuracies. For rou-
tine analysis of plasmas containing unknown concentrations of
THC, at least 1 out of every 6 samples should be a spiked standard.
Figure 2 shows a typical selected ion current profile with peaks
corresponding to 5 ng/ml of THG-TMS and 20 ng/ml of THC
2H2-TMS, while figure 3 is a standard curve for the THC concentra-
tion range 1 to 100 ng/ml of plasma. Precision data for various con-
centrations of THC in plasma are listed in table 1.
EXTRACTION OF HEMOLYZED BLOOD
The described procedure has proven to be a reliable method for
the analysis of THC in plasma and normal whole blood samples.
However, attempts to analyze hemolyzed and badly decomposed
blood samples gave erratic results due to poor extraction efficien-
cies. Both the THC originally in the blood and the added deuter-
ium-labeled THC apparently are tightly bound to something in the
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FIGURE 2. Selected ion current profiles for quantitation of -THC in plasma.
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FIGURE 3. Standard curve for measurement of THC in 1-ml plasma samples.
TABLE 1. Precision Data for Measurement of THC
Added to Plasma*
-THC Added Relative Standard
(ng/ml) Deviation (%)
* 4 samples analyzed twice at each concentration.
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hemolyzed blood, thereby preventing efficient extraction with
hexane. Rosenthal and Brine reported a procedure for extraction of
THC from cadaver blood (6). A simpler procedure was developed at
Battelle for extraction of THC from hemolyzed blood. The proce-
dure gave acceptable quantitative results for concentrations of
THC down to 1 ng/ml for most batches of hemolyzed blood. Howev-
er, occasionally large variations in extraction efficiency did occur,
indicating that the method deserves further attention.
Figure 4 is a flow diagram for the extraction procedure used for
hemolyxed blood. An ethanol solution of the deuterium-labeled in-
ternal standard is added to 1 ml of hemolyzed blood followed by 1
ml of 3 N H2SO4 and 1 ml of high purity acetonitrile. The mixture
is sonicated and the resulting protein precipitate removed after
centrifugation. The supernatant is then neutralized with 3 N
NaOH and 1 ml of pH 7.0 buffer added. The aqueous solution is
extracted twice with 6 ml of high purity hexane. The remaining
steps involving successive washing of the hexane extract with
dilute alkali and dilute acid followed by concentration and derivati-
zation are identical to the procedure for extraction of THC from
normal plasma.
QUANTITATION OF 9-CARBOXY- THC AND 11-HYDROXY-
THC IN PLASMA
The 11-hydroxy- THC metabolite has psychotomimetic activity
comparable to that of THC. Consequently, any study attempting
to relate behavior effects to THC blood concentrations should also
include analysis of the 11-hydroxy metabolite blood concentrations.
Although the 9-carboxy metabolite has no psychomimetic activity,
it is a major THC metabolite, and its concentration in both blood
and urine can be measured for a longer period of time than the
concentration of THC. Consequently, there has been strong in-
terest in developing methods for quantitation of these two metabo-
lites in blood and other body fluids. A method capable of simulta-
neously measuring plasma concentrations of THC and the two me-
tabolites would be particularly attractive.
Rosenfeld has published a method for simultaneous quantitation
of THC and the 11-hydroxy- -THC in plasma involving extrac-
tion into toluene followed by back extraction of phenolic com-
pounds into Claisen’s alkali and derivatization prior to GC/MS
analysis (7).
A method for determination of -THC, cannabinol, and 11-hy-
droxy- -THC has been developed at the Research Triangle Insti-
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FIGURE 4. Flow diagram for analysis of THC in hemolyzed blood.
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tute (8). After addition of deuterated internal standards to the
plasma, the cannabinoids are extracted into petroleum ether con-
taining 1 percent isoamyl alcohol. Chromatography on Sephadex
LH-20 is used to partially purify the cannabinoids. The THC and
cannabinol are collected in one fraction and analyzed by GC/MS
without derivatization. The 11-hydroxy- -THC is collected in a
later eluting fraction and converted to its bis-(trimethylsilyl) de-
rivative prior to GC/MS analysis. The same publication (8) de-
scribes a separate procedure for analysis of the 9-carboxy metabo-
lite of THC in plasma or urine. After addition of the deuterated
analog as the internal standard, acetone is added to the body fluid
to precipitate proteins, The acetone is removed by evaporation and
the aqueous residue extracted with diethyl ether. Reverse phase
high performance liquid chromatography is used to purify the car-
boxy metabolite which is subsequently converted to its dimethyl de-
rivative by treatment with dimethyl sulfate. GC/MS with electron
impact ionization is used for quantitative determination of the
ratio of metabolite to internal standard.
A procedure for measurement specifically for 9-carboxy- -THC
was reported by Nordquist et al. (9). The method uses the isomer
of the metabolite as the internal standard. After acidification of
the plasma (pH 4), it is extracted with diethyl ether and the con-
centrated extract treated with diazomethane to form the methyl
ester of the carboxy metabolite. The methylated extract is then
partially purified by chromatography on Sephadex LH-20. Finally,
trimethylsilylation of the phenolic OH is achieved just prior to
quantitation by GC/EI-MS.
Investigation of LC/MS Analysis of 9-Carboxy- THC
In May 1978 Battelle acquired a Finnigan LC/MS system which
utilizes a moving belt to transport the eluent from a liquid chroma-
tographic column into the ion source of a Finnigan 4000 mass spec-
trometer. The system offers the potential for direct analysis of
polar metabolites such as the 9-carboxy THC without derivatiza-
tion. Experiments were conducted to determine the sensitivity of
this system for measurement of the metabolite. Figure 5 shows the
ion current profile obtained by depositing on the moving belt, by
means of a syringe, a hexane solution containing 1 ng of the 9-car-
boxy- THC. Unfortunately, this sensitivity could not be ap-
proached when the metabolite was passed through a reverse phase
HPLC column and then onto the moving belt. The major causes for
dramatically reduced sensitivity appeared to be increased back-
ground due to the solvent system and a longer period of elution.
Because of the relatively poor sensitivity of the LC/MS for this
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compound, attention was shifted to development of a GC/MS
method.
FIGURE 5. Ion current profile for MH+ of 9-carboxy- THC introduced into the
mass spectrometer via the LC/MS interface.
GC/MS Method
A procedure was sought for simultaneously extracting THC
and the two metabolites of interest from plasma. This was achieved
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by modifications of the previously described procedure for extrac-
tion of THC from plasma. The major changes consisted of use of
a more polar solvent and elimination of the dilute alkali wash.
Also, the best GC/MS reproducibility was experienced when the ex-
tracted carboxy metabolite was first converted to its methyl ester
prior to trimethylsilylation of the phenolic group.
FIGURE 6. Flow diagram for simultaneous analysis of THC, 11-hydroxy- -THC,
and 9-carboxy- THC in plasma.
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Figure 6 is a flow diagram for the extraction of THC and its
two metabolites of interest from plasma. To 1 ml of plasma in a 20-
ml culture tube equipped with a Teflon-lined screw cap, add 1 ml of
a pH 2 buffer, followed by 100 µl of an ethanol solution containing
50 ng each of the deuterium-labeled internal standards ( THC
2H3, 11-hydroxy- THC-
2H3, and 9-carboxy- THC-
2H3). Vortex the
tube for 10 sec and then add 4 ml of a hexane-ethyl acetate solu-
tion (7:l v/v). Screw the cap on tightly and check for a leak. Slowly
rotate or rock the tube for 15 min. Loosen the cap and then centri-
fuge. Using a disposable Pasteur pipette, transfer the organic layer
(top) to a second culture tube and discard the aqueous plasma
layer. Add 2 ml of 0.2 N H2SO4 to the organic extract. Screw on the
cap, tighten, and again check for a leak. Repeat the rocking (10
min) and centrifugation (10 min). Transfer the organic layer (top)
to a 15-ml centrifuge tube. Be careful not to transfer any of the
aqueous (lower) layer to the centrifuge tube. Discard the aqueous
layer. Gently concentrate the extract to near dryness at a tempera-
ture of 35-40°C using a nitrogen stream. Wash down the sides of
the centrifuge tube with 0.5 ml of high purity methanol. Vortex
the tube for 10 sec and again evaporate to near dryness. Wash
down the sides of the centrifuge tube with 0.2 ml of methanol.
Vortex the tube for 10 sec and then transfer the methanol solution
to a 1-ml glass vial having a cone-shaped bottom and equipped with
a Teflon-lined screw cap. High purity diethyl ether (0.5 ml) is used
for a final wash of the centrifuge tube and the ether combined with
the methanol in the 1-ml vial. Evaporate the combined solvents to
near dryness using a gentle stream of nitrogen while gently heat-
ing the vial (  40°C). To form the methyl ester of the carboxy meta-
bolite, add a solution of diazomethane in diethyl ether until the
yellow color persists. Cap the vial and heat at 50°C for 0.5 hr. Cool
the vial to room temperature, remove the cap, and evaporate the
solvent to near dryness under a gentle stream of nitrogen. Add 50
µl of bis-(trimethylsilyl) acetamide containing 1 percent trimethyl-
silyl chloride to the vial, cap tightly and heat at 90°C for 1 hr. The
sample is now ready for GC/MS analysis, or it may be stored in a
freezer (–10°C) until it is to be analyzed.
For GC/MS analysis a 1.8-m × 2-mm glass column packed with 3
percent OV-17 on 100/120 mesh Gas Chrom Q (Applied Science
Labs, State College, PA) can be used. However, at THC concentra-
tions below about 10 ng/ml, interference by an endogenous, acidic
component of plasma prevents accurate measurement of the THC
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FIGURE 7. Selected ion current profiles for packed column GC/MS analysis of
THC.
peak height (see figure 7). The interfering peak can be resolved
from the THC peak by use of a capillary column.
Figure 8 shows the selected ion current profiles corresponding to
the protonated-molecule ions for THC-TMS (m/z 387) and
THC-2H3-TMS (m/z 390) from an analysis conducted on a 15-m glass
capillary (0.25 mm I.D.) coated with SE-52.
In this example, the THC was present at a concentration of
only 1 ng/ml, and it is well resolved from other peaks in the chro-
matogram, in contrast to the packed column selected ion current
profile (figure 7) where the peak, due to the THC-TMS, is com-
pletely obscured by the interfering peak. The capillary column
assay involves a splitless injection at a column temperature of
160°C of 2 µl of the silylated extract plus 1 µl of n-tetradecane
which gives enhanced GC resolution due to the so-called “solvent
effect” (10). After 1 min the column temperature is rapidly pro-
grammed to 250°C. Under these conditions all three of the canna-
binoids are eluted within 6 min as shown in figure 9.
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FIGURE 8. Selected ion current profiles for capillary column GC/MS analysis of
THC.
In order to achieve maximum sensitivity, only two ion masses
are monitored at a given time during the GC/MS analysis. Thus,
the ion masses corresponding to the protonated-molecule ions for
THC-TMS and its deuterated analog are monitored during their
elution window. Then, under computer control, the mass analyzer
voltages are switched so that the ions corresponding to the proton-
ated-molecule ions for the ll-hydroxy -THC-TMS and its deuter-
ated analog are monitored. Finally, the mass analyzer voltages are
set to monitor the protonated-molecule ion currents for the methyl
ester of the 9-carboxy- -THC-TMS and its deuterated analog. A
computer printout of the resulting ion current profiles is shown in
figure 10.
Improved capillary column GC resolution can be achieved with-
out lengthening the analysis time by using hydrogen as the carrier
gas rather than helium or methane (11). Furthermore, the combi-
nation of hydrogen and ammonia gives better quality CI mass spec-
tra than the combination of helium and ammonia. The hydrogen/
ammonia CI mass spectra for each of the trimethylsilylated canna-
binoids are shown in figure 11.
FIGURE 9. Total ion current chromatogram from capillary column GC/MS analysis
of standard mixture of the trimethylsilylated cannabinoids.
FIGURE 10. Computer printout of selected ion current profiles for GC/MS analysis
of THC and two of its metabolites.
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FIGURE 11. CI-MS (H2/NH3) of trimethylsilylated cannabinoids.
Despite the high resolving power of capillary column GC and the
specificity of ammonia CI-MS, it is evident from figure 10 that in-
terfering peaks are still a potential problem. This is largely due to
the relatively unselective extraction method used. An additional
negative consequence of the extraction procedure is that the life-
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FIGURE 12. Blood concentrations of THC and two of its metabolites following
oral administration of 10 mg of the drug to a human subject.
time of the capillary column is shortened due to the buildup of in-
tractable, coextracted materials at the front of the column. There-
fore, there is need for further work to develop a more selective ex-
traction and sample cleanup method which is still amenable to rou-
tine analysis of multiple samples.
The described method for quantitation of THC and the two
metabolites has been applied to measurement of the plasma con-
centrations of these compounds following oral administration of 10
mg of THC to human volunteers. Figure 12 shows the concentra-
tions versus time curves for a representative case.
ACKNOWLEDGMENT
These studies were supported by National Institute on Drug
Abuse Contract HSM-42-72-183.
118 FOLTZ AND HIDY
REFERENCES
1. S. Agurell, B. Gustafsson, B. Holmstedt, K. Leander, J.-E. Lindgren, I. Nilsson,
F. Sandbery, and M. Asberg. Quantitation of tetrahydrocannabinol in plasma
from cannabis smokers. J. Pharm. Pharmacol., 25, 554 (1973).
2. D. Rosenthal, T.M. Harvey, J.T. Bursey, D.R. Brine, and M.E. Wall. Comparison
of gas chromatography mass spectrometry methods for the determination of
tetrahydrocannabinol in plasma. Biomed. Mass Spectr., 5, 312-316 (1978).
3. R.L. Foltz, P.A. Clarke, B.J. Hidy, D.C.K. Lin, A.P. Graffeo, and B.A. Petersen.
Quantitation of tetrahydrocannabinol and 11-nor- tetrahydrocannabinol-9-
carboxylic acid in body fluids by GC/CI-MS. In J.A. Vinson (ed.), Cannabinoid
Analysis in Physiological Fluids, ACS Symposium Series 98, American Chemical
Society, Washington, D.C., 59-71 (1979).
4. D.L. Fenimore, C.M. Davis, J.H. Whitford, and C.A. Harrington. Vapor-phase si-
lylation of glassware. Anal. Chem., 48, 2289-2290 (1976).
5. R.L. Foltz. Quantitative analysis of abused drugs in physiological fluids by gas
chromatography/chemical ionization mass spectrometry. In A.P. de Leenheer,
R.R. Roncucci, and C. van Peteghem (eds.), Quantitative Mass Spectrometry in
Life Sciences II, Elsevier Scientific Publishing Co., Amsterdam, 39-62 (1978).
6 .  D .  R o s e n t h a l  a n d  D .  B r i n e .  Q u a n t i t a t i v e  d e t e r m i n a t i o n  o f
tetrahydrocannabinol in cadaver blood. J. Forensic Sci., 24, 282-290 (1979).
7. J. Rosenfeld. The simultaneous determination of tetrahydrocannabinol and
11-hydroxy- tetrahydrocannabinol in plasma. Anal. Letters, 10, 917-930 (1977).
8. M.E. Wall, D.R. Brine, J.T. Bursey, and D. Rosenthal. Detection and quantita-
tion of tetrahydrocannabinol in physiological fluids. In J.A. Vinson (ed.), Canna-
binoid Analysis in Physiological Fluids, ACS Symposium Series 98, American
Chemical Society, Washington, D.C., 39-57 (1979).
9. M. Nordquist, J.-E. Lindgren, and S. Agurell. A method for the identification of
acid metabolites of tetrahydrocannabinol by mass fragmentography. In R.E. Wil-
lette (ed.), Cannabinoid Assays in Humans, NIDA Research Monograph 7,
DHEW Pub. No. (ADM)78-339. Supt. of Docs., U.S. Govt. Print. Off., Washington,
D.C., 64-69 (1976).
10. K. Grob and K. Grob, Jr. Splitless injection and the solvent effect. J. High Reso-
lution Chromatogr. and Chromatogr. Commun., 1, 57-64 (1978).
11. K. Grob and G. Grob. Practical capillary gas chromatography-a systematic ap-
proach. J. High Resolution Chromatogr. and Chromatogr. Commun., 2, 109-117
(1979).
AUTHORS
Rodger L. Foltz
Center for Human Toxicology
University of Utah
Salt Lake City, Utah 84112
Bruce J. Hidy
Battelle Memorial Institute
505 King Avenue
Columbus, Ohio 43201
Analysis of Cannabinoids
Research Monograph 42, R. Hawks, Editor
National Institute on Drug Abuse, 1982
Stability of Delta-9-
Tetrahydrocannabinol in Stored
Blood and Serum
Anthony S. Wong, Michael W. Orbanosky, Victor C.
Reeve, and James D. Beede
INTRODUCTION
The literature has described delta-9-tetrahydrocannabinol (
THC) as a degradable molecule, subject to dissipation when exposed
to oxidation (1), elevated temperatures, and active surfaces such as
glass and plastic which contribute (2-6) to the loss of THC from
aqueous media by extensive and sometimes irretrievable binding.
Since our work deals principally with the analysis of THC in
blood, concern developed regarding whether THC would exhibit
similar instability in blood samples stored over relatively long peri-
ods. This study was designed to evaluate long term storage when
THC is present in blood in high physiological concentrations. We
examined the dissipation rate of THC during storage, the effects
of elevated temperatures on blood-THC samples, the effects of re-
petitive freeze/thaw cycles on blood-THC samples, and the effects
of agitation and ambient temperature fluctuation during mailing.
EXPERIMENTAL DESIGN
All blood and serum samples in this study were spiked with
THC at a concentration of 50 ng/ml by adding 50 ng of THC dis-
solved in 5 µl of alcohol to each ml of blood or serum. All glass-
ware containing the concentrated standards was silylated prior to
use. Glassware used to contain blood-THC samples was left untreat-
ed. The quantitative analytical procedure used in this study in-
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volved the addition of 50 µl of C-11 deuterated THC to 1.0 ml of
blood or serum, acidification of the sample to pH 4-5 using 3 ml 0.1
M KH2PO4 followed by multiple 5 ml extractions with 1.5% isoa-
myl alcohol in pentane. The combined organic phases were evapo-
rated just to dryness and the residue dissolved in 50 µl of 0.1 M
trimethylphenyl ammonium hydroxide, of which 5 µl were injected
into the GC/MS. The fundamental difference between this method
and that developed by Rosenfeld (5) is the absence of a prior
cleanup of the extract.
A Finnigan 3200 GC/MS interfaced with a two-channel program-
mable multiple ion monitor (PROMIM) was employed for the anal-
ysis. Gas chromatography was conducted on a 60 × 0.4 cm glass
column containing 1.5% SP-2250/1.95% SP-2401 on 100/120 Supel-
coport at 210°C. Selected ions were monitored at m/e 328 and m/e
331, the molecular ions for methylated THC and its deuterated
analog, respectively. Figure 1 and figure 2 represent an ion chro-
matogram for THC and a typical standard curve for unextracted
THC versus 5 ng deuterated THC.
The precision and accuracy of the analytical method in hemo
lyzed blood and serum were determined by spiking replicates at
two concentration levels: 10 ppb (10 ng THC in 5 µl of ethanol to
1 ml of substrate) and 50 ppb (50 ng of THC in 5 µl of ethanol to
1 ml of substrate). All the replicates of the same substrate were
analyzed on the same day immediately after spiking.
1. Long Term Storage: 1.0 ml samples of spiked blood or
serum were prepared and stored in glass under nitro-
gen at 5°C, under ambient atmosphere at 5°C, -5°C,
and -20°C. Storage stability was evaluated on a bi-
weekly basis.
2. Elevated Temperature: Triplicates of 1.0 ml samples of
blood and serum were stored and maintained at 20°,
30°, 40°, 50° and 60°C for 25 hours prior to analyses.
3. Repetitive Freeze/Thaw Cycles: Triplicate 1.0 ml sam-
ples of blood and serum were frozen at -20°C for 8 days
during which time the samples were allowed to thaw
for 4 hours each day and refrozen. Analyses were per-
formed on the eighth day.
4. Mailing Effect: THC (50 µg in 5 µl of ethanol) was
spiked to 1.0 ml of hemolyzed blood and serum in 2 ml
glass bottles equipped with Teflon-lined screw caps.
The containers were then mailed to southern Califor-
nia, returned to Sacramento, and the THC ana-
lyzed.
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FIGURE 1. Ion chromatogram of hemolyzed blood sample spiked with 10 ppb of
delta-9-THC.
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FIGURE 2.
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Standing curve of THC co-injected with THC-D3. The curve covers
range of 0 to 50 ng of THC in the original blood sample.
the
RESULTS
Relative recoveries and assay reproducibility of THC in ten
replicate analyses of 1.0 ml blood and serum samples spiked at con-
centrations of 50 ng/ml and 10 ng/ml respectively were deter-
mined. Mean recoveries for blood at the 50 ng/ml and 10 ng/ml
blood levels were 100% (CV=4%) and 97% (CV= 5%), respectively.
1 . THC appeared to remain stable in blood up to and
including week 17. The analyses conducted on the
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samples stored to weeks 19, 21, and 23 showed signifi-
cantly lower concentrations, indicating that loss of
THC begins at approximately week 19. Complete in-
ability to detect THC occurred at week 23. High re-
covery of THC from serum was achieved up to week
13. Starting from week 15, however, lower and irregu-
lar analyses were obtained. As in the case of blood,
definite losses of THC occurred after 19 weeks in
storage.
2. In both blood and serum samples, neither atmospheric
conditions nor storage temperatures contributed sig-
nificantly to the recovery of THC. Delta 9-THC was
found to be stable in blood samples when stored at
60°C for 25 hours. In serum, THC could be recov-
ered from samples stored at 50°C for 25 hours. At 60°C
the serum matrix gelled, which inhibited extraction.
3. Both blood and serum samples containing -THC can
be repeatedly frozen and thawed without showing sig-
nificant losses of the drug.
4. There was no significant loss from the substrates with
agitation in mailing during normal handling with the
containers utilized.
DISCUSSION
The sudden losses of THC that occurred around the 17th week
in storage cannot be sufficiently explained. It is thought, nonethe-
less, that the losses are not due to actual degradation or sudden
surface adsorption of the -THC molecule. Rather, it is surmised
that the dissipation of THC may be due to the inability success-
fully to extract the drug, possibly owing to irretrievable binding of
the molecule to degrading proteins.
The recovery data from the replicate analyses of the spiked sam-
ples clearly indicate the suitability of the analytical method for de-
tection of -THC in both hemolyzed blood and serum. Comparison
of the ion chromatogram of a typical hemolyzed blood sample
spiked with 10 ppb of -THC (figure 1) and the standard curve
(figure 2) shows that the peak of the molecular ion, 328, of methy-
la ted THC is about 50% of full scale with a noise level of less
than 5% of full scale. The calculated detection limit of -THC
should be between 1 and 2 ppb (1 to 2 ng/ml of blood). This detec-
tion limit is comparable to that reported by other researchers
(2,5,7). Since the physiological levels normally observed in marijua-
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na users range from 1 ng/ml to 100 ng/ml in blood (1), the method
developed during the present study to evaluate the in vitro, stabil-
ity of THC can also be used to determine the THC in the
blood of the smokers.
The analytical technique is time-consuming and the CC/MS in-
strumentation is expensive. Therefore, the technique is not a prac-
tical screening procedure. The use of deuterated THC as an in-
ternal standard is essential in obtaining precise and accurate re-
sults.
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The Constituents of Cannabis and
the Disposition and Metabolism of
Cannabinoids
Richard L. Hawks
INTRODUCTION
Humans consume cannabinoids primarily by smoking prepara-
tions of Cannabis sativa L. When cannabis plant material is pre-
pared for purposes of intoxication, it is referred to as “marijuana.”
Cannabis that is used as an intoxicant comes from many different
geographical sources around the world and is referred to as “drug
type” cannabis because it contains significant quantities of
tetrahydrocannabinol (THC), the primary chemical ingredient of
the plant material responsible for the psychopharmacological
effect. Another type of cannabis equally prevalent worldwide is re-
ferred to as “hemp type” because originally, about four centuries
ago, it was cultivated for the manufacture of rope material. Canna-
bis is not in fact a plant indigenous to the New World; it was intro-
duced to the Western Hemisphere by Spanish explorers, who used
large amounts of hemp rope in their shipping industry.
More than 60 cannabinoid compounds have been identified in the
“drug type” cannabis used illicitly today. Some of the more impor-
tant ones are illustrated in figure 1. In addition, as in any plant
material, there is a large number of other chemical compounds
present, several hundred of which have been identified in cannabis
(1).
Though cannabis contains many cannabinoid components and
other chemical substances, THC is the most prominent psychoac-
tive cannabinoid component, and its concentration determines the
“potency” of marijuana. Other cannabinoids may contribute to
THC’s activity through interactions or direct effects on certain spe-
cific pharmacologic measures, but THC is the compound on which
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FIGURE 1. Cannabinoids of primary interest found in Cannabis Sativa.
most studies to date have concentrated. The psychopharmacologic
activities of either cannabinol or cannabidiol, for instance, are esti-
mated to be less than 10% as great in man as that of THC itself (2).
The predominant factor affecting potency is the genetic stock of
the plant. Seeds derived from cannabis of relatively high THC con-
tent will produce plants of relatively high potency, other factors
being equal. It should also be noted that the relative amounts of
cannabinoids in the plant can vary significantly depending on how
and where the plant is grown and harvested. Soil, climate, cultiva-
tion, and age can have considerable effect on the final “product.”
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Samples of marijuana from illegal shipments, confiscated be-
tween 1979 and 1982 by the Drug Enforcement Administration and
analyzed by the NIDA potency monitoring program, averaged
above 3.0% THC by weight. Potency has increased significantly
since the program started in 1974, when confiscated material was
found to contain less than 0.5%. A cannabis preparation called
“sinsemilla” has become increasingly available over the last 4
years and is currently averaging about 6% THC. Occasional sam-
ples with potencies as high as 10% have been encountered. The po-
tential for ingesting psychologically dysphoric amounts of THC is
thus much increased with the availability of these more potent
forms of cannabis.
The THC in marijuana is predominantly in the form of THC-
2-(and a small amount of 4-)-carboxylic acid (also called
“tetrahydrocannabinolic acids” or “THC-acids”) (1). These THC-
acids are changed rapidly into THC itself when they are subjected
to the heat of the burning cigarette. The burning process also
causes pyrolytic destruction of a portion of the THC and THC acid
in the cigarette. The actual amount of THC delivered in the smoke
has been estimated at 20% to 70% in experiments conducted with
smoking machines (3). The estimate of 70% is derived from a study
in which the cigarette was burned with a continuous draw, and
20% was found when a 5-second puff each minute was used. The
latter rate is the standard for tobacco smoking experiments. Mari-
juana smokers probably fall in between these estimates since they
usually inhale longer and more frequently than once a minute for
5 seconds. This assumption is supported by a study which deter-
mined that the bioavailability of THC from marijuana cigarettes as
measured in blood of human subjects ranged from 8% to 24%
(mean 18±6%) in 11 subjects (4). This “bioavailability” is the frac-
tion of THC in the cigarette which reaches the bloodstream. If for
instance, 35% of the THC in the cigarette were delivered in the
smoke and 50% of this passed through the lung to the blood, a
bioavailability of 17.5% would result, which is within the reported
range.
For the past 10 years NIDA has supplied cannabis cigarettes for
use in animal and human research on marijuana toxicity, pharma-
cology, pharmacokinetics, and chemistry. The cigarettes are sup
plied in potencies ranging from 0.5% to 3% by weight. The plant
material is grown under controlled conditions, and the material is
chemically characterized by quantitative analysis of eight major
cannabinoids. The cigarettes are supplied in a form similar in size
to unfiltered tobacco cigarettes.
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Other THC dosage forms developed by NIDA and made available
for research include oral doses of THC in sesame oil contained in
gelatine capsules, intravenous solutions of THC which are either
suspended in human serum albumen or dissolved in ethanol, and
ophthalmic preparations of THC in mineral oil. Each of these
dosage forms has its own unique time course of effect and metabol-
ic profile. Even though these dosage forms were developed for use
in research directed at consequences of marijuana abuse, they have
also served as dosage forms for studies in several areas of therapeu-
tic research. The oral form is under investigation as an antiemetic
drug for patients undergoing cancer chemotherapy, and the oph-
thalmic preparation is being investigated as a treatment to relieve
intraocular pressure resulting from glaucoma.
METABOLISM AND DISPOSITION
When cannabis is smoked or ingested orally, THC and the many
other cannabinoids present undergo extensive metabolism into
many oxygenated species. Most of the research on cannabinoid me-
tabolism has been carried out on THC itself. Metabolites of THC
which have been characterized and isolated from man (5,6,7) are il-
lustrated in figure 2.
The total number of metabolites resulting from human adminis-
tration of THC is undoubtedly much greater. In vitro and in vivo
animal studies indicate that a large number of hydroxylated and
carboxylated metabolites result from the metabolism of THC as
well as from the other cannabinoids found in the plant (8-14). In-
vestigators have also shown the presence of fatty acid conjugates of
THC (15,16), a variety of 0-glucuronides (17,18), and C-glucuronides
(19).
The formation of glucuronide conjugates of THC and its metabo-
lites has been reported to occur on the phenolic position (17), on
the carboxylic acid position in 11-nor- -THC-9-carboxylic acid (9-
carboxy-THC) (18), and directly on the two and four positions of the
aromatic ring (19). It is unclear at this time how this conjugation
affects excretion, storage, and recirculation of material, but it is
clear that a major portion of the cannabinoid metabolites excreted
in urine are in the form of glucuronide conjugates (5,18,20). In the
case of 9-carboxy-THC, conjugation may occur at both the phenolic
and the carboxy position, thus leading to the possibility of three
different conjugated species. A recent study has provided the char-
acterization of 12 additional acid metabolites of THC (21). An ex-
tensive and complex cannabinoid metabolic profile in man is indi-
METABOLISM AND DISPOSITION OF CANNABINOIDS 129
130 HAWKS
cated when all the possible cannabinoid metabolites and their re-
spective conjugates are considered.
The metabolite concentrations in figure 3 are typical of the sig-
nificant differences found in blood after oral administration (22) of
THC as compared with administration via smoking (23). The 11-hy-
droxy metabolite probably plays a minor role after smoking as the
concentration is very low (5), less than 10% of the THC concentra-
tion at any time. After oral administration, however, 11-OH-THC
may play a more important role as its concentration is relatively
higher in blood, often higher than that of THC. Significant
amounts of THC are not observed after oral administration owing
primarily to the relatively slow absorption of THC and subsequent
extensive metabolism via the “first pass” through the liver. The
blood profile of the oral dose indicates 9-carboxy-THC as the pre-
dominant metabolite.
FIGURE 3. Plasma concentration versus time curve for THC and its metabolites
after oral and smoked administrations.
Several of the hydroxylated metabolites have been shown to have
some activity (24), but 9-carboxy-THC has shown little or no activi-
ty when administrated to either man (24) or animal. The only
active metabolite known to occur in any significant concentration
is 11-hydroxy- THC, which has been shown to have activity equal
to or perhaps slightly greater than THC itself when administered
alone to man (25). The psychopharmacological activity in man of 8-
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beta-hydroxy-THC has been reported as about 4% of that of
THC and 8-alpha-hydroxy-THC less than 10% (24).
In human studies it has been shown that 80% to 90% of the total
dose of THC administered is excreted within 5 days, mostly (65%)
in feces (26). The urinary fraction, which makes up the remaining
18% to 23% of the dose excreted, consists primarily of acidic meta-
bolites such as 9-carboxy-THC and other related acids (21). Only
about 5% of the total urinary fraction consists of neutral cannabin-
oids, and THC itself makes up less than 1 % of this. The endpoint of
the renal pathway is therefore multi-oxygenated acidic metabolites.
The feces fraction consists of approximately equal parts neutral
and acidic metabolites, 9-carboxy-THC making up about 29% of the
extracted metabolites, THC about 8%, and 11-hydroxy-THC about
21% (5).
When the time course of the disappearance of THC from plasma
is compared with the very slow excretion of metabolites in urine, it
becomes obvious that some mechanism is contributing to this re-
tarded elimination of material. As mentioned above, 80% to 90% of
the THC dose administered IV is accounted for in 5 days, the re-
mainder being eliminated slowly over a longer period of time. One
mechanism which probably contributes significantly to the long ex-
cretion of these metabolites involves enterohepatic recirculation,
since the major portion of IV doses in humans is eliminated in the
feces (26) and reabsorption of biliary excreta has been demonstrat-
ed in the dog (27). Other mechanisms which could contribute in-
clude renal reabsorption and deeptissue distribution. Because of
the lipid solubility (28) of THC, a characteristic shared by many of
its metabolites, some portion of the dose is probably trapped in
fatty-tissue pools for slow release. Preferential absorption of THC
into the fat tissue of rats has been reported, while other tissues
such as brain, lung, and muscle absorbed a much smaller propor-
tion of the dose (29).
It is important to define both the mechanisms involved in this
slow excretion and what specific metabolites are involved. Even
though the acid metabolites are not likely to have psychoactivity,
other types of toxic effects cannot be excluded. The characteriza-
tion of fatty-acid conjugates of THC has led to speculation that spe-
cies of this type may contribute to storage of cannabinoids in body
tissue (15,161. Much research remains to be done to ascertain the
chronic toxicity of these or the many other THC metabolites.
The character of the metabolites and their mode of elimination is
important since the elimination process is measured in days, not
hours, and repeated administration via marijuana smoking likely
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leads to accumulation of both THC and metabolites and the possi-
bility of subsequent toxic consequences.
Much of the forensic interest in cannabinoid analysis of body
fluids has focused on the 9-carboxy-THC metabolite, the principal
acid metabolite of THC that has been characterized and synthe-
sized for study. This metabolite is an important species in both
blood and urine. As illustrated in figure 3, THC levels which are
initially quite high drop very rapidly and cross the rising 9-car-
boxy-THC curve at approximately 20 minutes. Although this curve
is based on a single dose, it does give credence to the hypothesis
that a blood analysis which shows similar concentrations for both
THC and 9-carboxy-THC could be an indication of very recent ad-
ministration of marijuana and perhaps of a high probability that
the subject is in an intoxicated state. This figure also illustrates
that, because of the rapid decrease in the concentration of THC in
blood, analytical methodology less sensitive than 1 or 2 nanograms
per milliliter is not likely to detect the presence of THC after sev-
eral hours except perhaps in a heavy chronic smoker. The curve
for 9-carboxy-THC in this figure shows a considerably longer time
course and therefore provides a better indicator of previous smok-
ing.
Urine metabolite assays which have recently become available
on the commercial market have made cannabinoid detection avail-
able to a much broader spectrum of laboratories including those as-
sociated with the armed forces, with private industry, and penal in-
stitutions. These methods include the SYVA Co. EMIT system and
the Roche Diagnostics ABUSCREEN RIA system. The analysis of
urine using these types of assays provides an indication of past use
of marijuana. Due to the relatively long detection period of canna-
binoid metabolites in urine, this ‘past use’ cannot be more specifi-
cally pinpointed than between 1 hour and 1 week. This makes any
urine analysis, regardless of the levels detected, inadequate for pre-
diction of intoxication or specific time of use.
As mentioned above, a blood analysis does have the potential for
providing information relevant to intoxication. Blood samples are,
however, difficult to obtain for many forensic purposes because of
their invasive nature. Saliva and breath are much easier samples
to acquire for drug detection and both have been investigated for
the presence of marijuana components after smoking. The use of
TIC methods for detection of THC in saliva has been suggested by
several authors (30-34).
A study in humans using radiolabeled THC administered by in-
travenous injection (35) failed to detect any radioactivity in saliva
samples. This suggests that neither THC or its metabolites pass
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into the saliva or lung from the blood and that cannabinoids de
tected in these biological matrices are sequestered during the
smoking process.
In a recent study, an RIA specific for THC was used (36) to ana-
lyze a set of saliva samples (37) from subjects who smoked marijua-
na cigarettes containing cannabis of approximately 2% potency.
Mixed saliva samples were taken from these subjects over a 24-
hour period. The concentration of sequestered THC in these sam-
ples, illustrated in figure 4, is subject to considerably more fluctu-
ation over time than plasma levels due to the inherent variability
of mixed saliva concentration and to the difficulty in precisely ali-
quoting from a mixed saliva sample. It is clear, however, that sig-
nificant levels of THC remain in saliva for several hours after
smoking marijuana. During the first hour, in the absence of food
intake, some levels exceeded 100 ng/ml and levels above 5 ng/ml
FIGURE 4. Human saliva levels after smoking a single marijuana cigarette
containing 18 mg THC. N=8 at 20 min., N=7 at 60 min., N=5 for others.
Variability expressed as standard deviation.
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were still detectable in most samples beyond 8 hours even though
normal food and liquid intake was resumed after 3 hours.
These results give further indication that saliva could be a useful
fluid for presumptive detection of recent use. Even though no quan-
titative correlation can be made between saliva levels and intoxica-
tion since only sequested THC is being detected, the capacity to
reduce the “past use” time frame from weeks to hours could have
useful research and forensic applications.
The use of breath as a screening medium has been investigated
using solvent and cryogenic traps with subsequent analysis by
HPLC/MS (38) and also using solid matrix traps followed by con-
ventional RIA (39). The levels in breath appear to be lower than
those found in saliva after smoking, and use of such a medium for
detection would consequently require relatively more sensitivity in
the assay method as well as a more complex means of sample col-
lection.
PHARMACOKINETICS
Studies of the pharmacokinetics of THC have been receiving in-
creasing emphasis in the last few years as analytical techniques for
the quantitative determination of cannabinoids in biological fluids
have improved. The pharmacokinetics of THC and its metabolites
is important to several research areas. A variety of studies have
suggested that long-term, chronic use of marijuana may lead to ad-
verse health effects in the individual (40). Some of these effects
could be related to a toxic accumulation of either THC or metabo-
lites of THC in the body. Pharmacokinetic studies of the mecha-
nisms by which these cannabinoids are eliminated from the body
are important in understanding the potential extent and rate of
this accumulation.
Detailed pharmacokinetic studies of THC in humans under both
acute and chronic dosing schedules are beginning to provide the
basic data that will allow blood levels of active drug to be related
to psychotomimetic, behavioral, and physiological effects (4,23,26).
With the increasing availability of analytical methods for analysis
of cannabinoids in blood and urine, there is increasing interest in
providing analytical data for forensic purposes which can be relat-
ed to the intoxication of individuals involved in accidents, as well
as individuals who are legally liable for drug-taking behavior in
the armed forces, on probation, or in industry. It is important to
understand the kinetic mechanisms involved with THC and other
cannabinoids in order to relate these forensic questions to the
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meaning of a given blood level, particularly in cases where intoxi-
cation is a factor. The availability of more sensitive and more ac-
cessible analytical technology for the quantitative analysis of mari-
juana components in body fluids will play a key role in these ef-
forts.
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they can be applied, their chances for success, and needed future
research.
GPO Stock #017-024-01180-1 $5.50 NTIS PB #85-159663/AS $22
48 MEASUREMENT IN THE ANALYSIS AND TREATMENT OF SMOKING
BEHAVIOR. John Grabowski, Ph.D., and Catherine S. Bell, M.S..
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ettings.
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49 PROBLEMS OF DRUG DEPENDENCE, 1983: PROCEEDINGS OF THE 45TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
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50 COCAINE: PHARMACOLOGY, EFFECTS, AND TREATMENT OF ABUSE. John
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51 DRUG ABUSE TREATMENT EVALUATION: STRATEGIES, PROGRESS, AND
PROSPECTS. Frank M. Tims. Ph.D., ed. A state-of-the-art review
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52 TESTING DRUGS FOR PHYSICAL DEPENDENCE POTENTIAL AND ABUSE
LIABILITY. Joseph V. Brady, Ph.D., and Scott E. Lukas, Ph.D.,
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depressants, hallucinogens, cannabinoids, and dissociative
anesthetics.
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54 MECHANISMS OF TOLERANCE AND DEPENDENCE. Charles Wm. Sharp,
Ph.D., ed. Review of basic knowledge concerning the mechanism of
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DEPENDENCE, INC. Louis S. Harris, Ph.D., ed.
IN PRESS OR PREPARATION
53 PHARMACOLOGICAL ADJUNCTS IN SMOKING CESSATION.
John Grabowski, Ph.D., ed.
56 ETIOLOGY OF DRUG ABUSE: IMPLICATIONS FOR PREVENTION. Coryl
LaRue Jones, Ph.D., and Robert J. Battjes, D.S.W., eds.
57 SELF-REPORT METHODS OF ESTIMATING DRUG USE: MEETING CURRENT
CHALLENGES TO VALIDITY. Beatrice A. Rouse, Ph.D., Nicholas J.
Kozel, M.S., and Louise G. Richards, Ph.D., eds.
58 PROGRESS IN THE DEVELOPMENT OF COST-EFFECTIVE TREATMENT FOR
DRUG ABUSERS. Rebecca S. Ashery, D.S.W.. ed.
59 CURRENT RESEARCH ON THE CONSEQUENCES OF MATERNAL DRUG ABUSE.
Theodore M. Pinkert. M.D., J.D., ed.
60 PRENATAL DRUG EXPOSURE: KINETICS AND DYNAMICS. C. Nora
Chlang, Ph.D., and Charles C. Lee, Ph.D., eds.
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